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ABSTRACT 
Shanker Swaminathan 
 
ROLE OF GENOMIC COPY NUMBER VARIATION IN ALZHEIMER'S DISEASE AND 
MILD COGNITIVE IMPAIRMENT 
 
Alzheimer's disease (AD) is the most common form of dementia defined by loss in 
memory and cognitive abilities severe enough to interfere significantly with daily life 
activities. Amnestic mild cognitive impairment (MCI) is a clinical condition in which an 
individual has memory deficits not normal for the individual's age, but not severe enough 
to interfere significantly with daily functioning. Every year, approximately 10-15% of 
individuals with MCI will progress to dementia. Currently, there is no treatment to slow or 
halt AD progression, but research studies are being conducted to identify causes that 
can lead to its earlier diagnosis and treatment. 
 
Genetic variation plays a key role in the development of AD, but not all genetic factors 
associated with the disease have been identified. Copy number variants (CNVs), a form 
of genetic variation, are DNA regions that have added genetic material (duplications) or 
loss of genetic material (deletions). The regions may overlap one or more genes 
possibly affecting their function. CNVs have been shown to play a role in certain 
diseases. 
 
At the start of this work, only one published study had examined CNVs in late-onset AD 
and none had examined MCI. In order to determine the possible involvement of CNVs in 
AD and MCI susceptibility, genome-wide CNV analyses were performed in participants 
from three cohorts: the ADNI cohort, the NIA-LOAD/NCRAD Family Study cohort, and a 
vii 
unique cohort of clinically characterized and neuropathologically verified individuals. 
Only participants with DNA samples extracted from blood/brain tissue were included in 
the analyses. CNV calls were generated using genome-wide array data available on 
these samples. After detailed quality review, case (AD and/or MCI)/control association 
analyses including candidate gene and genome-wide approaches were performed. 
 
Although no excess CNV burden was observed in cases compared to controls in the 
three cohorts, gene-based association analyses identified a number of genes including 
the AD candidate genes CHRFAM7A, RELN and DOPEY2. Thus, the present work 
highlights the possible role of CNVs in AD and MCI susceptibility warranting further 
investigation. Future work will include replication of the findings in independent samples 
and confirmation by molecular validation experiments. 
 
Andrew J. Saykin, PsyD, Chair 
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I. Introduction 
 
A. Alzheimer's disease 
 
Alzheimer's disease (AD) is the most common form of dementia accounting for 50-80% 
of dementia cases. Dementia is a general term which includes symptoms such as loss in 
memory and cognitive abilities severe enough to interfere significantly with daily life. AD 
is a progressive disease in which dementia symptoms gradually worsen over time. The 
most common early symptom is difficulty in remembering new information. Difficulty in 
remembering names and recent events, apathy and depression are other early 
symptoms of the disease. The individual's cognitive and functional abilities decline as the 
disease progresses. Impaired judgment, behavior changes, confusion, disorientation, 
and speaking, swallowing, and walking difficulties are later symptoms of the disease. 
 
The hallmark abnormalities of AD are the accumulation of beta-amyloid protein 
fragments (amyloid plaques) in between nerve cells (neurons) in the brain and the 
accumulation of twisted strands of tau protein (neurofibrillary tangles) inside neurons 
(Figure 1). Synapses are specialized connections between neurons that enable 
information flow between individual neurons. It is believed that in AD, the accumulation 
of beta-amyloid outside the synapses interferes with neuron-to-neuron communication 
and leads to cell death. Abnormally high levels of tau inside the neuron form 
neurofibrillary tangles, which block transport of nutrient and other essential molecules 
throughout the cell possibly leading to cell death. 
 
An estimated 5.4 million Americans of all ages, including 5.2 million individuals aged ≥65 
years, and 200000 individuals aged <65 years have AD [1]. It is the sixth leading cause 
2 
of death across all ages in the United States and the fifth leading cause of death in 
Americans aged ≥65 years. Amnestic mild cognitive impairment (MCI) is a clinical 
condition in which an individual has memory deficits not normal for the individual's age, 
but not severe enough to interfere significantly with daily functioning. Approximately 14-
18% of individuals aged 70 years and older in the population have MCI, and 10-15% of 
these individuals are likely to progress to dementia, particularly AD each year [2]. 
 
Although there are no current treatments that can slow or halt the progression of AD, 
there are treatments that can temporarily slow the worsening of dementia symptoms and 
possibly improve the quality of life in individuals with AD and their caregivers. The U.S. 
Food and Drug Administration has approved two types of medications to treat the 
cognitive symptoms of AD: cholinesterase inhibitors (Aricept, Exelon, Razadyne, 
Cognex) and memantine (Namenda) (Alzheimer’s Association: 
http://www.alz.org/alzheimers_disease_standard_prescriptions.asp). A large worldwide 
research effort is also underway to identify the causes of AD that can lead to its earlier 
diagnosis and better treatment. 
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Figure 1. Representative images of a neuritic plaque (A) and neurofibrillary 
tangles (B). Adapted from Castellani et al. (2010) [3]. 
 
 
       A      B  
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B. Role of genetic variation in Alzheimer's disease 
 
Genetic variation is known to play a key role in the development and progression of AD. 
AD has a high heritability with 58-79% of phenotypic variation estimated to be caused by 
genetic factors [4]. Based on the age of onset, AD can be classified into two subtypes: 
early-onset AD and late-onset AD [5]. Early-onset AD with an age at onset roughly 
ranging from 30 to 60 or 65 years accounts for approximately one to six percent of all 
cases. Among the early-onset AD cases, approximately 60% have multiple AD cases 
within their families, and of these familial early-onset AD cases, 13% have an autosomal 
dominant inheritance pattern with at least three generations affected [5, 6]. Around 
several hundred families carry mutations in three genes: APP (amyloid beta (A4) 
precursor protein) on chromosome 21q, PSEN1 (presenilin 1) on chromosome 14q and 
PSEN2 (presenilin 2 (Alzheimer disease 4)) on chromosome 1q (Table 1), but these 
accounts for less than 1% of cases. A review of the role of these genes can be found in 
Bekris et al. (2010) [5]. A number of mutations have been identified in these genes and 
information regarding these mutations can be found in Alzheimer Disease and 
Frontotemporal Dementia Mutation Database 
(http://www.molgen.ua.ac.be/ADMutations/) [7]. 
 
Late-onset AD, the more common form of AD (>90% of all cases), has an age at onset 
later than 60 or 65 years. A number of genetic association studies have been performed 
in AD and these have been catalogued in the AlzGene database 
(http://www.alzgene.org/) [8]. The leading genetic risk factor for late-onset AD is the 
APOE (apolipoprotein E) ε4 allele on chromosome 19q. The ε4 allele, a member of a 
three allele haplotype composed of ε2, ε3 and ε4 alleles confers a dose-dependent 
increase in AD risk of approximately four-fold in carriers compared to non-carriers [9-11]. 
5 
Large case-control genome-wide association studies (GWASs) have identified and 
replicated other AD risk loci including: CLU, CR1, PICALM, BIN1, EXOC3L2, MTHFD1L, 
MS4A4A/MS4A6E, CD2AP, CD33, ABCA7 and CUGBP2 [12-19]. A summary of 
published GWASs in AD can be found in Table 2. However, for the strongest SNPs at 
each of CR1, CLU, PICALM, BIN1, EPHA1, MS4A, CD33, CD2AP and ABCA7 loci, the 
population attributable fractions (the proportional reduction in mortality or population 
decrease if a risk factor exposure were reduced to an alternative ideal exposure 
scenario) were estimated to between 2.72% and 5.97%. Furthermore, the cumulative 
population-attributable fraction for these non-APOE loci is estimated to be as much as 
35% [17]. Thus, the identified loci do not account for all the genetic variation associated 
with the disease. It is possible that other forms of genetic variation such as copy number 
variations (CNVs) may play a role. 
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Table 1. Genes associated with early-onset familial Alzheimer’s disease. Adapted 
from Bekris et al. (2010) [5] and Alzheimer Disease and Frontotemporal Dementia 
Mutation Database: 
http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=1&ML=6&Page=StatPerGene 
AD-Alzheimer’s disease; EOFAD-Early-onset familial Alzheimer’s disease. 
 
AD 
Loci 
Gene 
Symbol 
Gene Name Chromosome % of 
EOFAD 
Number of 
mutations 
Number of 
families 
AD1 APP amyloid beta 
(A4) precursor 
protein 
21q21.3 10-15 32 89 
AD3 PSEN1 presenilin 1 14q24.3 18-50 185 405 
AD4 PSEN2 presenilin 2 
(Alzheimer 
disease 4) 
1q31-q42 Rare 13 22 
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Table 2. Summary of published genome-wide association studies in Alzheimer's 
disease. Adapted from the AlzGene database: http://www.alzgene.org/largescale.asp; 
updated 18 April 2011. AD-Alzheimer's disease; GWAS-Genome-wide association 
study; SNP-Single nucleotide polymorphism. 
 
Study Design Number 
of SNPs 
Number of 
AD cases 
in GWAS 
(follow-up) 
Number of 
controls in 
GWAS 
(follow-up) 
Featured genes 
Abraham et al. 
(2008) [20] 
Case-control 561494 1082 (-) 1239 
(1400) 
APOE, LRAT 
Beecham et al. 
(2009) [21] 
Case-control 532000 492 (238) 496 (220) APOE, FAM113B 
Bertram et al. 
(2008) [22] 
Family-based 484522 941 (1767) 404 (838) APOE, ATXN1, 
CD33, 
GWA_14q31.2 
Carrasquillo et 
al. (2009) [23] 
Case-control 313504 844 (1547) 1255 
(1209) 
APOE, PCDH11X 
Coon et al. 
(2007) [24] 
Case-control 502627 664 (-) 422 (-) APOE 
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Study Design Number 
of SNPs 
Number of 
AD cases 
in GWAS 
(follow-up) 
Number of 
controls in 
GWAS 
(follow-up) 
Featured genes 
Grupe et al. 
(2007) [25] 
Case-control 17343 380 (1428) 396 (1666) ACAN, APOE, 
BCR, CTSS, 
EBF3, FAM63A, 
GALP, 
GWA_14q32.13, 
GWA_7p15.2, 
LMNA, 
LOC651924, 
MYH13, PCK1, 
PGBD1, TNK1, 
TRAK2, UBD 
Harold et al. 
(2009) [12] 
Case-control 529205 3941 
(2023) 
7848 
(2340) 
APOE, CLU, 
PICALM 
Heinzen et al. 
(2009) [26] 
Case-control Not 
available 
331 (-) 368 (-) APOE, CHRNA7 
Hollingworth et 
al. (2011) [18] 
Case-control 496763 6688 
(13182) 
13685 
(26261) 
ABCA7, BIN1, 
CD2AP, CD33, 
CR1, EPHA1, 
MS4A4E, MS4A6A 
Hu et al. 
(2011) [27] 
Case-control 509376 1831 (751) 1764 (751) APOE, BIN1 
Lambert et al. 
(2009) [13] 
Case-control 537029 2032 
(3978) 
5328 
(3297) 
APOE, CLU, CR1 
9 
Study Design Number 
of SNPs 
Number of 
AD cases 
in GWAS 
(follow-up) 
Number of 
controls in 
GWAS 
(follow-up) 
Featured genes 
Lee et al. 
(2011) [28] 
Case-control 627380 549 (2449) 544 (1390) DGKB, 
GWA_10q23.1, 
GWA_18q23, 
GWA_3q25.2, 
HPCAL1 
Li et al. (2008) 
[29] 
Case-control 469438 753 (418) 736 (249) APOE, GOLM1, 
GWA_15q21.2, 
GWA_9p24.3 
Naj et al. 
(2010) [16] 
Case-control 483399 931 (1338) 1104 
(2003) 
APOE, MTHFD1L 
Naj et al. 
(2011) [17] 
Case-control 2324889 
(imputed) 
8309 
(3531) 
7366 
(3565) 
APOE, BIN1, 
CD2AP, CD33, 
CLU, CR1, 
EPHA1, MS4A4A, 
PICALM 
Poduslo et al. 
(2009) [30] 
Case-control 
and Family-
based 
489218 9 (199) 10 (225) TRPC4AP 
Potkin et al. 
(2009) [31] 
Case-control 
and 
quantitative 
trait 
516645 172 (-) 209 (-) APOE, ARSB, 
CAND1, EFNA5, 
MAGI2, PRUNE2, 
TOMM40 
Reiman et al. 
(2007) [32] 
Case-control 312316 446 (415) 290 (260) GAB2 
Seshadri et al. 
(2010) [15] 
Case-control 2540000 
(imputed) 
3006 
(6505) 
22604 
(13532) 
APOE, BIN1, CLU, 
EXOC3L2, 
PICALM 
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Study Design Number 
of SNPs 
Number of 
AD cases 
in GWAS 
(follow-up) 
Number of 
controls in 
GWAS 
(follow-up) 
Featured genes 
Sherva et al. 
(2011) [33] 
Case-control 2540000 
(imputed) 
124 (-) 142 (-) AGPAT1, 
ATP6V0A4, 
GLOD4, RGS6, 
TMEM132C 
Wijsman et al. 
(2011) [19] 
Case-control 
and Family-
based 
565336 1848 (617) 1991 (573) APOE, CELF2 
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C. Copy number variation 
 
Recent advances in genome-wide technologies such as comparative genome 
hybridization (CGH), single nucleotide polymorphism (SNP) microarrays, and genome 
sequencing have led to identification of structural variants termed CNVs, ranging in size 
from one kilobase (kb) to several megabases (Mb) not previously identifiable by 
chromosome banding. These structural variants are present in variable copy number on 
comparing two or more genomes, and can include simple addition (copy number gains 
or duplications) or loss (copy number losses or deletions) of genetic material, or more 
complex rearrangements [34, 35]. The present work focuses only on deletions and 
duplications. CNVs can be inherited or sporadic; and may encompass one or more 
genes possibly affecting their function. The phenotypic effects of CNVs depend mainly 
on whether the genomic rearrangement affects dosage-sensitive genes or regulatory 
sequences. CNVs have been catalogued in a number of databases such as the Toronto 
Database of Genomic Variants (http://projects.tcag.ca/variation/) [36], DECIPHER 
(Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl 
Resources; http://decipher.sanger.ac.uk/) [37] and ECARUCA (European 
Cytogeneticists Association Register of Unbalanced Chromosome Alterations; 
http://umcecaruca01.extern.umcn.nl:8080/ecaruca/ecaruca.jsp) [38]. 
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D. Mechanisms for formation of copy number variations 
 
The processes that could be involved in the formation of CNVs have been described in 
Stankiewicz and Lupski (2010) [35] and are summarized below. Figure 2 shows a 
representation of the recurrent and nonrecurrent rearrangements associated with 
genomic disorders. 
 
1. Nonallelic Homologous Recombination 
 
Low-copy repeats (LCRs) or segmental duplications are deoxyribonucleic acid (DNA) 
fragments that are >1 kb in size and have >90% DNA sequence identity. Many LCRs 
have complex structure and those that are >10 kb and have ~97% sequence identity can 
result in local genomic instability. Misalignment of chromosomes or chromatids that 
mediate nonallelic homologous recombination (NAHR) can result in unequal crossing-
over [39], with recombination hotspots, gene conversion, and apparent minimal efficient 
processing segments. NAHR between directly oriented LCRs can result in deletions or 
reciprocal duplications of the genomic segment between them. When LCRs are inverted, 
NAHR leads to an inversion of the intervening genomic segment. When LCRs have a 
complex structure consisting of both direct and inverted subunits, they may be 
substrates for NAHR leading to genomic deletions/duplications and inversions 
respectively. The vast majority of the common-sized recurrent rearrangements, i.e. 
reciprocal deletions and duplications, or inversions, have been shown to be caused by 
this molecular mechanism. 
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2. Nonhomologous End Joining 
 
Nonrecurrent genomic rearrangements have been thought to arise by nonhomologous 
end joining (NHEJ), a recombination-based mechanism responsible for repair of DNA 
double strand breaks. In this mechanism, double strand breaks are detected; then both 
broken DNA ends undergo bridging, modification, and ligation [40]. Unlike NAHR, LCRs 
or minimal efficient processing segments are not required by NHEJ to mediate 
recombination. The process may also be stimulated by the genomic architecture. Often, 
additional nucleotides at the DNA end junction are contained in the product of repair 
leaving a “molecular scar” [41]. 
 
3. Replication-Error Mechanisms 
 
A mechanism that has recently been shown to be involved in the origin of genomic-
disorder-associated non-recurrent rearrangements that have a complex structure is fork 
stalling and template switching (FoSTeS), a mechanism based on DNA replication error 
[42, 43]. Here, the DNA replication fork can stall and the lagging strand is disengaged 
from the original template. It switches to another replication fork in physical proximity and 
by priming the new fork reinitiates DNA synthesis on the new fork. Hastings et al. (2009) 
based on experimental observations in human, yeast and other model organisms, 
proposed a generalized replicative template-switch model termed the microhomology-
mediated break-induced replication (MMBIR) model, that may account for many of the 
structural variations seen in genomes and genes [44]. Based on the direction of fork 
progression and whether the lagging or leading strand in the new fork was used as a 
template and copied, the erroneously incorporated fragment from the new replication 
fork could be in the same direction or inverted relative to its original position. Also, the 
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template switching results in either a deletion or duplication depending on whether the 
new fork is located upstream or downstream of the original fork. FoSTeS/MMBIR has 
been proposed to play a major role in generating structural variation including 
nonrecurrent CNVs and complex genomic rearrangements in the human genome, and 
even in the formation of LCRs [45, 46].  
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Figure 2. Representation of the recurrent (A) and nonrecurrent (B) genomic 
rearrangements that play a role in genomic disorders. (A) For the more common 
recurrent rearrangements, the same-sized deletions and duplications have both 
breakpoints mapping (clustering) within the low-copy repeats (LCRs) that are directly 
oriented. (B) For the nonrecurrent rearrangements, the breakpoints are scattered. The 
breakpoints group in the vicinity of a LCR if it is present. Adapted from Stankiewicz and 
Lupski (2010) [35]. 
 
 
           A 
 
            B  
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E. Methods for copy number variation detection 
 
A number of methods have been developed to assess copy number within genomic 
CNVs. A review of these methods can be found in Fanciulli et al. (2010) [47] and are 
briefly summarized below. For the present work, the SNP arrays: Illumina Human610-
Quad BeadChip and Affymetrix Genome-Wide Human SNP 6.0 Array were used. 
 
1. Comparative genome hybridization arrays 
 
CGH arrays have been widely used for CNV identification. To fabricate the arrays, a 
solid support (usually glass) is spotted with genomic DNA sequences. Different 
fluorescent markers are used to label the test and reference DNAs, which are then 
hybridized simultaneously to the array. The respective signal intensities are compared to 
assess the copy number. Constructing the arrays involves using DNA sequences 
ranging in size from 200 kb (bacterial artificial chromosome arrays) to 25 base pair (bp) 
(oligonucleotide array). 
 
2. Single nucleotide polymorphism arrays 
 
Arrays designed for the detection of SNPs can also be used to identify CNVs. This can 
be performed by determining differences in signal intensity independent of genotype. 
The current generation of SNP arrays are designed to provide greater genome-wide 
coverage and also to include non-polymorphic probes that have been optimized for 
measurement of copy number [48]. 
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3. Quantitative real-time polymerase chain reaction 
 
Quantitative real-time polymerase chain reaction (qPCR) is a commonly used method to 
screen targeted genomic regions for CNVs. It offers the advantages of being an efficient 
method for identification of deletions or duplications at single loci and also being a 
relatively high-throughput and technically straightforward assay. However, qPCR cannot 
be used for simultaneous amplification of many targets of interest in a single reaction, 
and as copy number estimates from these assays form a continuous distribution, it is 
also not possible to get precise integer measurements of gene copy number [49-51]. 
 
4. Paralogue ratio test 
 
The paralogue ratio test offers an accurate and relatively high-throughput method to 
obtain gene copy number at targeted single loci [50, 51]. The target element whose copy 
number is being determined and another unlinked reference locus are simultaneously 
amplified in the same reaction tube by the same primer pairs. The two regions are 
distinguished by internal differences such as amplicon length or restriction digest, 
quantified and compared to determine the target copy number compared to the 
reference. Simultaneous amplification of target and control in the same reaction helps 
reduce experimental variability and enables better precision of the measurements, 
generating copy number estimates close to integer values. 
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5. Multiplex ligation-dependent probe amplification and multiple amplifiable probe 
hybridization 
 
Simultaneous analysis of multiple genomic regions (up to 40 target sequences) can be 
performed using multiplex ligation-dependent probe amplification and multiple 
amplifiable probe hybridization, which are alternative target polymerase chain reaction 
(PCR)-based approaches [52]. In these approaches, oligonucleotide probes are used to 
generate locus-specific amplicons which can be resolved by capillary electrophoresis. 
Duplications are indicated by enhanced peak signals while deletions are indicated by 
reduced peaks. The techniques offer the advantages of being sensitive and simple to 
apply, and they can also be used for screening multiple targets in addition to their more 
common use for locus-specific studies. 
 
6. Sequencing and genome assembly comparison 
 
Structural variants have been successfully identified by alignment of DNA sequences 
from different sources. The development of high-throughput DNA sequencing protocols 
or so-called next-generation sequences has led to the generation of new assembles of 
complete genome sequences from single individuals enabling more robust and reliable 
genome comparisons and CNV identification when compared to earlier approaches [53, 
54]. Next-generation sequencing platforms have led to the development of new 
computational methods for identifying structural variations. The paired-end read mapping 
is a commonly used approach [54, 55]. A library of fragments (typically 300-500 bp of 
genomic DNA) is generated, followed by massively parallel deep sequencing, generating 
millions of short sequence reads from a given sample to determine the 'paired-end 
spans'. Structural variations are identified by comparing the size of the paired-end spans 
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to a reference genome. The method permits the identification of inversions and provides 
CNV boundary resolution at the single nucleotide level. However, it can detect only 
insertions smaller than the average insert size of the library, and variants located within 
complex genomic regions cannot be reliably identified by the method [56]. A new 
approach that incorporates a novel CNV calling algorithm (Event Wise Testing) designed 
for ad hoc analysis of read depth has been recently proposed [57]. Estimation of 
coverage is done in non-overlapping intervals across the genome providing a 
quantitative measure of copy number. Deletion or duplication events are indicated by a 
decrease or increase in read depth across multiple consecutive genomic windows 
respectively. However, a limitation of the method is that it cannot determine balanced 
rearrangements or structural variations involving highly repetitive sequences. It also 
shows limitations in identifying novel insertions or their precise location. Paired-end 
mapping and read depth offer different and complementary advantages, thus using both 
approaches together in next-generation sequence data may enhance detection of 
different structural variations. 
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F. Copy number variation detection algorithms 
 
A number of algorithms have been proposed for CNV detection using CGH and SNP 
arrays. These can be classified into several models such as smoothing methods, 
clustering methods, maximum likelihood procedures including Hidden Markov models 
(HMMs) and expectation-maximization algorithms. A review of these models can be 
found in Koike et al. (2011) [58]. A brief summary of the different models is given below. 
 
For smoothing methods, the simplest method is to use a moving average for smoothing 
log2ratio profiles and detecting duplicated or deleted regions over the specified 
thresholds [59]. The intensity of the target probe divided by that of the reference probe is 
the log2ratio. A quantile smoothing method based on L1 norm (the sum of absolute 
values) penalty minimization [60] and a wavelet de-noising method [61] have been 
proposed as more sophisticated smoothing methods. The cluster along with 
chromosomes method was developed as a clustering method, in which calculation of 
hierarchical clustering trees along each chromosome arm (or chromosome) is performed 
and the 'interesting' clusters are selected after considering the false discovery rate [62]. 
Although effective in simulation data, smoothing and clustering methods do not achieve 
a CNV detection performance comparable with other methods in CGH array 
experimental data [63]. 
 
A number of maximum likelihood-related approaches have been proposed to date. 
Genetic local search algorithms (memetic algorithms) for maximizing the likelihood by 
considering the penalty function of breakpoints were introduced by Jong et al. (2003) 
[64]. An adaptive method for estimating the penalty constant was developed by Picard et 
al. (2005) to avoid selecting a very large segmentation number for over fitting the given 
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data. In this method, the probe intensity profile (log2ratio) is assumed to be a Gaussian 
distribution, and maximizing the likelihood is used to estimate the number of segments 
[65]. Venkatraman and Olshen (2007) proposed a circular binary segmentation method, 
which also assumes the average probe intensity to have a Gaussian distribution [66]. 
This method introduces the likelihood ratio statistic for testing the null hypothesis where 
there is no change, and the alternative hypothesis where there is exactly one change at 
an unknown location. A permutation test is used and the hypothetical change-points are 
adopted if the null hypothesis is rejected. The change-points are recursively searched 
using overlapping windows [66]. 
 
An HMM is a statistical model where the system is thought to follow a Markov process 
[67-69]. In most HMM models, it is assumed that the probe intensity values or Log R 
Ratio (LRR, log2(Robserved/Rexpected), where R is the sum of probe intensities and Rexpected is 
obtained from linear interpolation of canonical genotype clusters) and B Allele Frequency 
(BAF, a normalized measure of the relative signal intensity ratio of the B and A alleles on 
the SNP array) or genotypes are independent. The copy number states of the probes 
are assigned to be hidden states with certain transition probabilities. The copy number 
state of each probe is obtained by maximizing the likelihood of observed data (probe 
intensity, LRR and BAF, or genotypes). 
 
Previous studies have compared different platforms and algorithms [58, 70-73]. 
However, each algorithm has its own set of parameters that need to be fine-tuned 
according to the data to obtain the best possible results [71]. Unfortunately, most 
software developers provide little or no guidance for evaluating and choosing optimal 
parameter settings for their algorithms. Even when identical raw data is used as the 
input, the quantity and quality of CNV calls can be different depending on the algorithm 
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used [72]. Thus, it has been suggested to try multiple algorithms and take the union of 
copy number regions for downstream association analyses, which may improve 
sensitivity [71-73]. It has also been suggested to use software designed specifically for 
the platform that was used to generate the data, as it has been shown that algorithms 
typically perform better when they have been developed specifically for a certain data 
type as compared to algorithms that are platform-independent or software that has been 
readapted for newer versions of an array. 
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G. Copy number variation in selected neuropsychiatric disorders 
 
CNVs have been shown to play a role in various neuropsychiatric disorders (Table 3). 
Representative studies for some of these disorders are summarized below. 
 
  
24 
Table 3. Examples of copy number variations and selected neuropsychiatric 
disorders. 
 
Disorder Possible gene/loci 
affected by copy 
number variation 
Reference(s) 
Mendelian disorders 
Williams-Beuren syndrome 7q11.23 Peoples et al. (2000) [74] 
Williams-Beuren-region 
duplication syndrome 
7q11.23 Berg et al. (2007) [75] 
Smith-Magenis syndrome 17p11.2 Chen et al. (1997) [76] 
Potocki-Lupski syndrome 17p11.2 Potocki et al. (2007) [77] 
22q11.2 deletion syndrome 
(DiGeorge syndrome and 
velocardiofacial syndrome) 
22q11.2 Edelmann et al. (1999) [78] 
22q11.2 duplication syndrome 22q11.2 Ensenauer et al. (2003) [79] 
Miller-Dieker lissencephaly 
syndrome 
17p13.3 Cardoso et al. (2003) [80] 
Complex disorders 
Alzheimer’s disease APP Rovelet-Lecrux et al. (2006) [81] 
Kasuga et al. (2009) [82] 
Attention-deficit hyperactivity 
disorder 
ASTN2, TRIM32 
A2BP1, AUTS2, 
CNTNAP2, IMMP2L 
Lionel et al. (2011) [83] 
Elia et al. (2010) [84] 
Autism NRXN1 
 
16p11.2 
Autism Genome Project 
Consortium et al. (2007) [85] 
Weiss et al. (2008) [86] 
Bipolar disorder GRM7, CNTNAP2, 
COMT, GNB1L 
Zhang et al. (2009) [87] 
Epilepsy AUTS2, CNTNAP2 Mefford et al. (2010) [88] 
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Disorder Possible gene/loci 
affected by copy 
number variation 
Reference(s) 
Parkinson disease SNCA 
PARK2 
Singleton et al. (2003) [89] 
Pankratz et al. (2011) [90] 
Schizophrenia NRXN1 
16p13.1 
Rujescu et al. (2009) [91] 
Ingason et al. (2011) [92] 
Tourette syndrome NRXN1, CTNNA3 Sundaram et al. (2010) [93] 
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1. Autism 
 
Autism spectrum disorder (ASD) is a group of complex neurodevelopmental disorders 
characterized by social impairments, communication difficulties, and restricted, 
repetitive, and stereotyped patterns of behavior. The most severe form of ASD is autistic 
disorder, also called autism or classical ASD. Other conditions include a milder form 
known as Asperger syndrome, and childhood disintegrative disorder and pervasive 
developmental disorder not otherwise specified (National Institute of Neurological 
Disorders and Stroke Autism Fact Sheet: 
http://www.ninds.nih.gov/disorders/autism/detail_autism.htm). 
 
A number of studies have examined the role of CNVs in ASD. The Autism Genome 
Project Consortium (2007) performed linkage and CNV analyses in 1181 families with at 
least two affected participants [85]. The authors were able to implicate candidate loci 
including the 11p12-p13 region and neurexins. Marshall et al. (2008) in their genome-
wide assessment for structural abnormalities identified novel loci at DPP6-DPP10-
PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1 and the 15q24 regions among 
others to play a possible role in ASD susceptibility [94]. Their results further implicated 
the SHANK3-NLGN4-NRXN1 postsynaptic genes. Microdeletions and microduplications 
at 16p11.2 [86, 95] and genomic rearrangements involving the NRXN1 gene [96, 97] are 
thought to play a role in autism susceptibility. Glessner et al. (2009) performed a whole-
genome CNV study on a cohort of 859 ASD cases and 1409 healthy children of 
European ancestry, and evaluated positive findings in an independent cohort of 1336 
ASD cases and 1110 controls of European ancestry [98]. The authors were able to 
identify new susceptibility genes encoding neuronal cell-adhesion molecules including 
the NLGN1 and ASTN2 genes enriched with CNVs in ASD cases compared to controls. 
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They also observed CNVs within or surrounding genes involved in the ubiquitin 
pathways including the UBE3A, PARK2, RFWD2 and FBXO40 genes not observed in 
controls. 
 
In a CNV analysis in 912 multiplex families from the Autism Genetics Resource 
Exchange collection and 1488 healthy controls, Bucan et al. (2009) were able to observe 
rare variants including exonic deletions at the NRXN1 gene and whole gene duplications 
encompassing UBE3A and several other genes in the 15q11-q13 region [99]. Other 
genes such as the BZRAP1 and MDGA2 genes were also identified. In their cohort of 
996 ASD participants of European ancestry and 1287 matched controls, Pinto et al. 
(2010) were able to identify numerous de novo and inherited CNVs implicating many 
novel ASD genes such as the SHANK2, SYNGAP1 and DLGAP2  genes, and the X-
linked DDX53-PTCHD1 locus [100]. They also observed an enrichment of CNVs that 
may play a disruptive role in functional gene sets involved in cellular proliferation, 
projection and motility, and GTPase/Ras signaling. In 42 extended families with ASD, 
Salyakina et al. (2011) identified regions on 7p21.3, 15q24.1, 3p26.3 and 12q24.32 that 
could be associated with ASD [101]. In a recent rare genome-wide CNV analysis in 1124 
autism families, Sanders et al. (2011) were able to find de novo duplications of the 
7q11.23 region to be significantly associated with ASD [102]. They were also able to 
identify rare de novo CNVs at additional regions including 1q21.1, 15q13.2-13.3, 
16p13.2 (encompassing the USP7 and C16orf72 genes) and the CDH13 locus. 
Cumulative data provided evidence for the association of rare de novo events at 
7q11.23, 15q11.2-13.1, 16p11.2 and NRXN1 regions with ASD. Rare microdeletions 
overlapping NRXN3 exons have also been observed in ASD-affected individuals [103]. 
Thus, these studies highlight the potential role of CNVs in ASD. 
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2. Bipolar disorder 
 
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that results 
in unusual changes in mood, energy, activity levels and the ability to carry out day-to-day 
tasks. The symptoms of bipolar disorder can be severe resulting in damaged 
relationships or affecting job or school performance (National Institute of Mental Health 
Bipolar Disorder: http://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-
index.shtml). 
 
A few studies have examined CNVs in bipolar disorder. Wilson et al. (2006) in a CNV 
analysis of post-mortem brain DNA from bipolar disorder cases, schizophrenia cases 
and controls (35 individuals in each category), were able to identify aberrations at four 
loci [104]. The aberrant loci contained the genes encoding the EFNA5, GLUR7, 
CACNG2 and AKAP5 proteins. All of these proteins are expressed in the brain and have 
potential roles in neuronal function. In a different study, a CNV in the GSK3β locus on 
3q13.3 was found with an increased frequency in bipolar disorder participants compared 
to controls [105]. The gene codes for glycogen synthase kinase, a key component of the 
Wnt signaling pathway. Zhang et al. (2009) performed a genome-wide CNV analysis in 
1001 bipolar and 1033 control participants [87]. Genes disrupted by singleton deletions 
in their cases were found to be significantly overrepresented in pathways categorized as 
important for psychological disorders and behaviors. The authors identified GRM7, 
CNTNAP2, COMT and GNB1L as genes of interest. Recently, Priebe et al. (2011) 
performed a genome-wide CNV analysis in 882 participants with bipolar disorder and 
872 population-based controls [106]. Two common CNVs on the 10q11 and 6q27 
regions were found to be overrepresented in bipolar disorder participants who had an 
early age-at-onset (≤21 years) compared with controls. The authors suggested an 
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influence of CNVs on the development of early-onset, but not late-onset bipolar disorder, 
and provided support for the hypothesis of an etiological difference between early-onset 
and late-onset bipolar disorder. In a genome-wide analysis of de novo CNVs in a cohort 
of 788 trios, Malhotra et al. (2011) observed a significant enrichment of de novo CNVs in 
bipolar disorder and schizophrenia cases compared to controls [107]. De novo CNVs 
were found to be enriched in early-onset bipolar disorder cases (age-at-onset≤18 years). 
 
3. Parkinson disease 
 
Parkinson disease (PD) is part of a group of conditions called motor system disorders 
caused by the loss of dopamine-producing brain cells. It generally affects people over 
the age of 50. The primary symptoms of the disease are tremor (trembling in hands, 
arms, legs, jaws and face), rigidity (stiffness of the limb and trunk), bradykinesia 
(slowness of movement), and postural instability (impaired balance and coordination) 
(National Institute of Neurological Disorders and Stroke Parkinson’s Disease Information 
Page: http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease.htm). 
 
A causal association for PD has been obtained for at least five genes: SNCA, PARK2, 
PINK1, DJ-1 and LRRK2. Simple mutations (missense, nonsense, silent, splice site, and 
untranslated region mutations), small insertions and deletions, and CNVs of these five 
genes have been shown to result in PD. A review of the role of these genes can be 
found in Nuytemans et al. (2010) [108] and Crosiers et al. (2011) [109]. Duplications and 
triplications of the SNCA gene locus have been described in individuals affected with 
PD. A more severe, early-onset form of PD is associated with triplications of the SNCA 
gene [89, 110], whereas the phenotype associated with SNCA gene duplication 
resembles the typical late-onset idiopathic PD [111, 112]. In a genome-wide study of 
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CNVs in 273 PD participants and 275 controls, Simon-Sanchez et al. (2008) identified 
CNVs within the PARK2 locus in both PD participants and controls [113]. In a recent 
CNV study in 816 cases and 856 controls, Pankratz et al. (2011) were able to replicate 
the association of CNVs of the PARK2 gene with PD [90]. They also identified genome-
wide significant CNVs in two novel genes (DOCK5 and USP32) associated with an 
increase in PD risk. These studies suggest a role of CNVs in PD susceptibility. 
 
4. Schizophrenia 
 
Schizophrenia is a chronic, severe, and disabling brain disorder that affects 
approximately one percent of Americans. The symptoms of schizophrenia include 
hallucinations, delusions, thought disorders, and cognitive symptoms (National Institute 
of Mental Health Schizophrenia: 
http://www.nimh.nih.gov/health/publications/schizophrenia/complete-index.shtml). 
 
A number of studies have been performed to determine the possible role of CNVs in 
schizophrenia and a few of these studies are mentioned here. Steffanson et al. (2008) 
identified three deletions on 1q21.1, 15q12.2 and 15q13.3 significantly associated with 
schizophrenia in two large samples of 1433 cases and 33250 controls, and 3285 cases 
and 7951 controls [114]. In a genome-wide survey of rare CNVs in 3391 participants with 
schizophrenia and 3181 controls, the International Schizophrenia Consortium (2008) 
observed deletions within the 22q11.2 region critical for velo-cardial-facial syndrome, as 
well as deletions on 15q13.3 and 1q21.1 [115]. Deletions in the 22q11.2 region have 
also been reported in other studies [116, 117], suggesting a possible role of this region 
in schizophrenia. Kirov et al. (2008) in a study of 93 schizophrenia and 372 control 
participants identified a deletion in the 2p16.3 region disrupting the NRXN1 gene and a 
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duplication in the 15q13.1 region spanning the APBA2 gene; both genes encode 
proteins that play a role in synaptic development and function [118]. A larger CNV study 
in 2977 schizophrenia participants and 33746 controls also identified the disruption of 
the NRXN1 gene to be associated with schizophrenia [91]. Support for the role of CNVs 
at the 16p13.1, 1q21.1 and NRXN1 regions in schizophrenia were also obtained in a 
Japanese study of 575 schizophrenia and 564 control participants [119]. CNVs in the 
16p13.1 region which includes the candidate genes NTAN1 and NDE1 have been 
recently shown to confer risk of schizophrenia in a study of 4345 schizophrenia and 
35079 control participants [92]. 
 
Another region identified to be a schizophrenia risk region is the 3q29 region. Deletions 
in this region have been identified in two studies: one study involving 245 schizophrenia 
and 490 control participants [120], and the other study involving 3945 schizophrenia or 
schizoaffective disorder participants and 3611 screened comparison participants [117]. 
The later study also confirmed the association of deletions in the 1q21.1, 15q13.3, and 
22q11.1 regions, duplications in the 16p11.2 region, and NRXN1 gene deletions with 
schizophrenia. Duplications in the vasoactive intestinal peptide receptor gene VIPR2 
were also identified in this study as well as in a different study of 8290 cases and 7432 
controls [121]. Grozeva et al. (2012) conducted a study to examine the frequencies of 
nine schizophrenia-associated CNV loci in 10259 individuals from the UK Wellcome 
Trust Case Control Consortium with non-psychiatric disorders [122]. The authors found a 
significantly higher frequency of deletions at 1q21.1, 3q29, 15q11.2, 15q13.1, 22q11.2, 
and duplications at 16p11.2 in schizophrenia cases compared to the non-psychiatric 
controls. These studies show that regions affected by CNVs may play an important role 
in schizophrenia susceptibility. A further review can be found in Lee et al. (2011) [123]. 
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5. Tourette syndrome 
 
Tourette syndrome (TS) is a neurodevelopmental disorder characterized by repetitive, 
stereotyped, involuntary movements and vocalizations called tics. Approximately 200000 
Americans have the most severe form of TS, and as much as one in 100 show milder 
and less complex symptoms such as chronic motor or vocal tics (National Institute of 
Neurological Disorders and Stroke Tourette Syndrome Fact Sheet: 
http://www.ninds.nih.gov/disorders/tourette/detail_tourette.htm). 
 
Sundaram et al. (2010) performed a genome-wide CNV analysis in 111 participants with 
TS and 73 ethnically matched controls [93]. They were able to identify five exon-affecting 
rare CNVs that were either de novo or recurrent in ten TS participants. Genes/loci in 
three of the five CNVs have been implicated by studies in other neurodevelopmental 
disorders including schizophrenia, autism, and attention-deficit hyperactivity disorder. In 
a recent case-control CNV analysis of 460 individuals with TS and 1131 controls, 
Fernandez et al. (2012) observed an enrichment of genes within histamine receptor 
signaling pathways as well as axon guidance, cell adhesion, nervous system 
development, and synaptic structure and function processes [124]. The authors also 
identified three large de novo events that they thought were likely pathogenic, including 
one disrupting multiple gamma-aminobutyric acid receptor genes. A significant overlap 
of genes mapping within rare CNVs in TS was observed with those identified in autism 
spectrum disorders. The two studies thus showed an overlap of genes within rare CNVs 
in TS with those identified in other neurodevelopmental disorders. 
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H. Copy number variation in Alzheimer's disease 
 
1. Early-onset Alzheimer's disease 
 
Rovelet-Lecrux et al. (2006) identified a duplication of the APP locus on chromosome 21 
in five French families with autosomal dominant early-onset AD and cerebral amyloid 
angiopathy [81]. A Dutch family having an autosomal dominant segregation pattern, and 
neuropathology compatible with AD and cerebral amyloid angiopathy was also identified 
to have an APP locus duplication [125]. Kasuga et al. (2009) examined the occurrence 
of the APP locus duplication in a Japanese AD cohort consisting of familial and early-
onset sporadic cases [82]. APP locus duplications were identified in two unrelated early-
onset familial AD families. A significantly higher APP mRNA expression level was 
observed in participants with the APP locus duplication in the peripheral blood when 
compared to age- and sex-matched controls. Although APP locus duplications were not 
identified in a screen of Swedish and Finnish participants with early-onset AD [126], a 
Swedish patient with early-onset AD was recently reported carrying an APP locus 
duplication [127]. Thus, a possible role for duplications at the APP locus exists in early-
onset AD warranting further examination. In order to determine if rare CNVs could play a 
role in autosomal dominant early-onset AD families without mutations in the APP, 
PSEN1 and PSEN2 genes as well as in rare sporadic young-onset AD cases, Rovelet-
Lecrux et al. (2011) performed a genome-wide CNV study in 21 unrelated autosomal 
dominant early-onset AD cases and 12 sporadic AD cases, with an onset age younger 
than 55 years [128]. Their analysis identified seven singleton CNVs, four of which target 
genes (KLK6, SLC30A3, MEOX2, and FPR2) that encode proteins relating to amyloid-
beta peptide signaling or metabolism. The authors suggest that the results of their study 
provide novel support for the amyloid cascade hypothesis. 
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2. Late-onset Alzheimer's disease and Mild cognitive impairment 
 
To our knowledge, only four studies other than the present work have investigated the 
role of CNVs in late-onset AD. Heinzen et al. (2010) performed a genome-wide scan of 
AD in 331 cases evaluated with a clinical diagnosis of dementia (>80% had a clinical 
diagnosis of AD) and 368 controls [26]. Although no CNVs were found to be significant, 
the authors identified a duplication in the CHRNA7 gene which they thought warranted 
further investigation. In a follow-up analysis of the CR1 region in a Flanders-Belgian 
cohort, Brouwers et al. (2011) identified a low-copy repeat associated CNV in the CR1 
region, producing different CR1 isoforms, CR1-F and CR1-S [129]. Significant 
association was obtained in carriers of CR1-S, and the authors were able to replicate 
this finding in a French cohort. In a case-only genome-wide CNV association study, 
Shaw et al. (2011) identified a chromosomal region on 14q11.2 encompassing a cluster 
of olfactory receptors to be associated with age of onset of AD [130]. Ghani et al. (2012) 
conducted a genome-wide scan for large CNVs among Caribbean Hispanics and 
identified a ~470 kb duplication on 15q11.2 to be nominally associated with AD [131]. To 
our knowledge, no study has investigated the role of CNVs in MCI. 
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I. Statement of purpose 
 
AD is the most common form of dementia and genetic variation represents one of the 
major risk factors in its development and progression. Recent genetic studies have 
identified a number of AD risk loci, but these do not account for all of the genetic 
variation associated with the disease. It is possible that other forms of genetic variation, 
such as CNVs, may be involved in disease susceptibility. CNVs, which are DNA regions 
present in variable copy number, have been implicated in a number of neuropsychiatric 
disorders such as autism, Parkinson disease and schizophrenia. However, at the time of 
starting of this work, only one published study had examined the role of CNVs in AD [26] 
and there were no published studies in MCI. The overall goal of this work was to 
determine if CNVs could be possible genetic risk factors in the development of AD and 
MCI. This would be accomplished through the following specific aims: 
 
I. Perform an initial CNV analysis in non-Hispanic Caucasian individuals from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort who had DNA samples 
extracted from peripheral blood. 
 
A. Compare the CNV burden between cases (AD and MCI participants) and 
controls. 
 
B. Identify through case/control association analyses genomic regions where 
CNVs were detected in cases but not in controls. 
 
II. Perform an initial CNV analysis using similar approaches as the ADNI study in non-
Hispanic Caucasian individuals from the National Institute of Aging-Late Onset 
36 
AD/National Cell Repository for AD (NIA-LOAD/NCRAD) Family Study who had DNA 
samples extracted from blood or brain tissue. 
 
A. Compare the CNV burden between cases (AD participants) and controls. 
 
B. Perform case/control association analyses to characterize genomic regions 
where CNVs were detected in cases but not in controls. 
 
C. Identify genomic regions also reported in the ADNI study to determine 
potential candidate AD regions. 
 
III. Perform an initial CNV analysis using similar approaches as the ADNI and NIA-
LOAD/NCRAD Family studies in Caucasian individuals from a unique cohort of clinically 
characterized and neuropathologically defined cases (AD participants) and controls who 
had DNA samples extracted from brain tissue. 
 
 A. Compare the CNV burden between cases and controls. 
 
B. Identify through case/control association analyses genomic regions 
overlapped by CNVs in cases but not in controls. 
 
C. Identify genomic regions reported in the ADNI and NIA-LOAD/NCRAD Family 
studies that replicate in this study to determine potential AD candidate regions. 
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II. Genomic Copy Number Analysis in Alzheimer’s Disease and Mild Cognitive 
Impairment: An ADNI Study 
 
A. Introduction 
 
Alzheimer’s disease (AD) is the most common cause of dementia and accounts for 50-
80% of dementia cases. Currently, an estimated 5.3 million Americans have AD, the 
seventh leading cause of death in the United States. The hallmark abnormalities of AD 
are deposits of the beta-amyloid protein fragments (plaques) and twisted strands of the 
tau protein (tangles). Amnestic mild cognitive impairment (MCI) is a clinical condition in 
which a person has problems with memory, with or without other cognitive deficits, that 
are noticeable to others and show up on psychometric testing but not severe enough to 
interfere significantly with daily functioning. About 14-18% of individuals aged 70 years 
and older have MCI, and these individuals are likely to progress to dementia, particularly 
AD, with an annual conversion rate of 10-15% [2]. 
 
Genetic factors play a key role in the development and progression of AD. AD has a high 
heritability, with 58-79% of phenotypic variation estimated to be caused by genetic 
factors [4]. Early-onset AD (onset earlier than 60 or 65 years) accounts for a small 
percentage (one to six percent) of cases and is primarily caused by mutations in three 
genes that affect the cerebral levels of beta-amyloid peptide: APP (amyloid beta (A4) 
precursor protein) on chromosome 21, PSEN1 (presenilin 1) on chromosome 14 and 
PSEN2 (presenilin 2 (Alzheimer disease 4)) on chromosome 1 [132]. Late-onset AD 
accounts for the majority of AD cases, but only the ε4 allele of the APOE (apolipoprotein 
E) gene on chromosome 19 has been consistently replicated across studies. At the time 
of performing this work, three large genome-wide association studies (GWASs) identified 
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five additional loci: CLU (clusterin), CR1 (complement component (3b/4b) receptor 1 
(Knops blood group)), PICALM (phosphatidylinositol binding clathrin assembly protein), 
BIN1 (bridging integrator 1), and EXOC3L2 (exocyst complex component 3-like 2) to be 
strongly associated with AD [12, 13, 15]. These loci also showed strong association in 
replication studies [14], further supporting a role in AD susceptibility. 
 
Copy number variants (CNVs) are segments of DNA, ranging from 1 kilobase (kb) to 
several megabases (Mb), for which differences in the number of copies have been 
revealed by comparison of two or more genomes. These differences can be copy 
number gains (duplications or insertional transpositions), losses (deletions), gains or 
losses of the same locus, or multiallelic or complex rearrangements. CNVs have been 
implicated in various neuropsychiatric disorders such as autism and schizophrenia [34]. 
At the time of performing this work, the role of CNVs in late-onset AD has only been 
examined in one study [26]. These authors performed a genome-wide scan of AD in 331 
dementia cases (in which >80% of patients had a clinical diagnosis of AD) and 368 
controls. Although no CNVs, which are typically rare cases, were significant at genome-
wide threshold, Heinzen et al. (2010) were able to identify a duplication in the CHRNA7 
gene warranting further investigation. At the time of performing this work, no study has 
looked at the role of CNVs in MCI. 
 
In the present report, we conducted a preliminary CNV analysis using genotype data 
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort to examine the role 
of CNVs in susceptibility to MCI and late-onset AD. ADNI is an ongoing multiyear public-
private partnership to test whether serial magnetic resonance imaging (MRI), positron 
emission tomography (PET), genetic factors such as single nucleotide polymorphisms 
(SNPs) and CNVs, other biological markers, and clinical and neuropsychological 
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assessments can be combined to improve early diagnosis and predict progression of 
MCI and early AD. Here, we used the genome-wide array data acquired on the ADNI 
cohort to determine whether AD and MCI participants (cases) showed an excess burden 
of CNVs relative to controls and to characterize any genomic regions where CNVs were 
detected in cases but not controls. 
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B. Methods 
 
1. Alzheimer’s Disease Neuroimaging Initiative 
 
The ADNI was launched in 2003 by the National Institute on Aging, the National Institute 
of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private 
pharmaceutical companies, and nonprofit organizations, as a $60 million, multiyear 
public-private partnership. The Principal Investigator of this initiative is Michael W. 
Weiner, MD, VA Medical Center and University of California-San Francisco. ADNI is the 
result of efforts of many coinvestigators from a broad range of academic institutions and 
private corporations. Presently, more than 800 participants, aged 55 to 90, have been 
recruited from over 50 sites across the US and Canada, including approximately 200 
cognitively normal older individuals (i.e. healthy controls or HCs) to be followed for three 
years, 400 people diagnosed with MCI to be followed for three years, and 200 people 
diagnosed with early AD to be followed for two years [133]. Longitudinal imaging, 
including structural 1.5 Tesla MRI scans collected on the full sample and [11C]Pittsburgh 
Compound-B- and [18F]fluorodeoxyglucose-PET imaging on a subset, and performance 
on neuropsychological and clinical assessments were collected at baseline and at 
follow-up visits in six-to-twelve intervals. Other biomarkers are also available including 
APOE and whole genome genotyping on the full ADNI sample, and longitudinal 
cerebrospinal fluid markers on a subset of the sample. Written informed consent was 
obtained from all participants, and the study was conducted with prior institutional review 
boards approval. Further information about ADNI can be found in [134] and at 
http://www.adni-info.org. 
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2. Participants 
 
Participants in the present analysis included 655 non-Hispanic Caucasian individuals 
from the ADNI cohort who had DNA samples extracted from peripheral blood. Those 
with DNA samples derived from cell lines were excluded from the present analysis 
because cell line transformation might influence CNV results [135, 136]. Current 
diagnoses were downloaded from the ADNI database as 04/29/2010 (AD=288, 
MCI=183, HC=184). In addition to AD participants who had a baseline and current 
diagnosis of AD, we included MCI participants who had converted from a baseline 
diagnosis of MCI to a current diagnosis of AD (MCI Converters) as well as one 
participant who had converted from a baseline diagnosis of HC to a current diagnosis of 
AD in the AD group. Similarly, in addition to MCI participants who had a baseline and 
current diagnosis of MCI, we included seven HC participants who had converted from a 
baseline diagnosis of HC to a current diagnosis of MCI in the MCI group. Data used in 
this analysis is publicly available on the ADNI website (http://adni.loni.ucla.edu). The 
focus of ADNI is on incident late-onset AD. To our knowledge, no participants in the 
present study carry a known causal mutation [5]. 
 
3. Genotyping 
 
Blood samples from each participant were obtained and sent to Pfizer for DNA extraction 
and were also banked at The National Cell Repository for Alzheimer’s Disease (NCRAD; 
http://ncrad.iu.edu). Genotyping was performed by the Translational Genomics Research 
Institute (Phoenix, AZ) using the Illumina Human610-Quad BeadChip as previously 
described [31, 137]. As indicated by the manufacturer’s documentation, the Human610-
Quad BeadChip contains 620901 markers. This array provides dense genomic coverage 
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(89%) in the CEU (Utah residents with Northern and Western European ancestry from 
the Centre d’Etude du Polymorphisme Humain collection) population analyzed here with 
a median marker spacing of 2.7 kb. In addition, 27635 markers are included in 
“unSNPable” regions likely to contain CNVs that are not easily assessed by SNPs. 
Coverage is provided for 3938 CNV regions (184064 markers) reported in the Toronto 
Database of Genomic Variants (http://projects.tcag.ca/variation/) at an average of 37.7 
markers per region. Markers have an average of 15-18-fold redundancy to improve 
signal quality for detection of CNVs (mean Log R Ratio standard deviation (SD)<0.2, see 
below). 
 
Normalized bead intensity data for each sample was loaded into GenomeStudioV2009.1 
software (Illumina, Inc., CA) along with the manufacturer’s cluster file to generate SNP 
genotypes. The Log R Ratio (LRR) and B Allele Frequency (BAF) values computed from 
the signal intensity files by GenomeStudio for each sample were exported and used for 
the generation of CNV calls. Initial genotyping was performed by the Translational 
Genomics Research Institute using BeadStudio software (Illumina, Inc., CA). In January 
2010, we reprocessed the array data using GenomeStudioV2009.1, and this dataset will 
be made available on the ADNI website in a follow-up data release. 
 
4. Inference of the Log R Ratio and B Allele Frequency 
 
The two alleles of an SNP are designated as allele A and allele B. GenomeStudio 
software uses a five-step six-degree of freedom affine transformation to normalize signal 
intensity values of the A and B alleles (referred to as X and Y). The normalized values 
are then transformed to a polar coordinate plot of normalized intensity R=Xnorm+Ynorm and 
composition (copy angle) θ=(2/pi)*arctan(Ynorm/Xnorm), where Xnorm and Ynorm represent 
43 
transformed normalized signals from alleles A and B for a particular locus (Illumina’s 
genotyping data normalization methods white paper). The LRR value for a sample is 
calculated as follows: 
LRR=log2(normalized R value/expected R value) for the SNP. 
 
Linear interpolation of the R value at the SNP’s θ value for a sample, relative to the R 
values of the surrounding clusters, is used to compute the expected R value. 
 
The BAF for a sample shows the θ value for an SNP, corrected for cluster positions, 
which were generated from a large set of previously studied normal individuals. BAF is 
described by the following equation: 
BAF=0 if θ<θAA 
       =0.5*(θ-θAA)/(θAB-θAA) if θ<θAB 
       =0.5+0.5*(θ-θAB)/(θBB-θAB) if θ<θBB 
       =1 if θ≥θBB, 
where θAA=mean θ value of all genotypes in AA cluster plotted in polar normalized 
coordinates, θAB=mean θ value of all genotypes in AB cluster plotted in polar normalized 
coordinates, and θBB=mean θ value of all genotypes in BB cluster plotted in polar 
normalized coordinates (GenomeStudio Genotyping Module v1.0 User Guide). 
 
5. Generation of copy number variation calls and quality control 
 
CNV calls were generated for the 655 non-Hispanic Caucasian participants whose DNA 
was derived from peripheral blood. PennCNV software (2009Aug27 version) 
(http://www.openbioinformatics.org/penncnv/), which implements a Hidden Markov 
model (HMM) model [68], was used to generate the CNV calls. The hg18 “all” PennCNV 
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Hidden Markov model (hmm), population frequency of B allele (pfb), and gcmodel files 
were used to ensure that CNV-specific markers were included. All samples were 
subjected to extensive quality control (QC). Since samples that have below optimal 
genomic wave QC values can be considered unreliable [138], we applied the GC-model 
wave adjustment procedure, using PennCNV’s gcmodel file. A frequency distribution plot 
of the number of CNV calls for all samples was made, and samples were excluded if the 
number of CNV calls made for that individual was greater than the 90th percentile of the 
frequency distribution. One sample was observed to have multiple deletions and 
duplications on chromosome 18 (Figure 3) and was excluded from further analysis as it 
may be a mosaic sample [139]. Samples were also excluded if they met the following 
criteria: LRR SD>0.35, BAF Drift>0.002, or Waviness Factor (WF)>0.04. The LRR SD is 
a measure of signal-to-noise ratio. Sometimes, when a sample has genotyping failure, 
many SNP markers will have abnormal BAF patterns (i.e., they do not cluster to 0, 0.5, 
or 1), yet their LRR looks normal. The BAF Drift takes into account these abnormal BAF 
patterns. The WF measures the waviness of the signal curves, as artificial gains and 
losses in the genome can be created by peaks and troughs of the wave. 
 
Analyses were also restricted to autosomes due to the complications of hemizygosity in 
males and X-chromosome inactivation in females. Finally, to ensure only high-
confidence CNVs were included in the analysis, CNVs for which the difference of the log 
likelihood of the most likely copy number state and less likely copy number state was 
less than 10 (generated using the confidence function in PennCNV), CNVs that were 
called based on data from fewer than 10 SNPs and CNVs that had more than 50% 
overlap with centromeric, telomeric, and immunoglobulin regions as defined in Need et 
al. (2009) [140] were excluded. 501 participants (AD=222, MCI=136, HC=143) passed 
all QC checks and included in further CNV analyses.  
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Figure 3. Representative image of B Allele Frequency and Log R Ratio of the 
participant in the ADNI cohort who had multiple deletions and duplications on 
chromosome 18. The orange shaded portion indicates regions with deletions and 
purple shaded portion indicates regions with duplications (Human Genome Build 36.1). 
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6. Case/control association analyses 
 
Case/control association analyses using CNV calls generated for the AD, MCI and HC 
participants were performed using PLINK v1.07 
(http://pngu.mgh.harvard.edu/~purcell/plink/) [141] to investigate any differences in CNV 
calls between cases and controls (AD versus HC; MCI versus HC). Two approaches 
were used: (1) a candidate gene approach using AD genes, identified from the AlzGene 
database (http://www.alzgene.org) [8] as having a positive association with AD in at least 
one study, consisting of 294 genes as of 04/22/2010, and (2) a whole genome approach 
using PLINK’s entire gene list (hg18 coordinates), consisting of 17938 genes. The 
AlzGene database provides a comprehensive and regularly updated synopsis of genetic 
studies in AD. In both approaches, CNV segments either partially or completely 
overlapping gene regions were analyzed. Both deletions and duplications were 
analyzed. 
 
Representative plots of CNV calls (Figure 6) were generated in UCSC Genome Browser 
(http://genome.ucsc.edu/) [142] (March 2006 (NCBI36/hg18) assembly). Plots were 
produced using the Genome Browser track for the Illumina Human-610 array obtained 
from the PennCNV website. Representative plots of LRR and BAF values for samples 
(Figures 3 to 5 and 7) were generated using the Illumina Genome Viewer plugin within 
GenomeStudio (Human Genome Build 36.1). 
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C. Results 
 
1. Description of copy number variation calls by current diagnostic group 
 
The sample demographics and CNV call characteristics of the 501 participants who 
passed all QC checks are shown in Tables 4 and 5. 
 
A total of 6737 CNV calls (4746 deletions and 1991 duplications) were observed in these 
participants. The average number of SNPs per CNV call was 25 and the average length 
of a CNV call was 105.93 kb. A higher CNV call rate and a lower average CNV call size 
were observed in deletions compared to duplications. On comparing the three diagnostic 
groups, AD and MCI participants appeared to have a higher CNV call rate for deletions 
and a lower CNV call rate for duplications, but these were not statistically significant 
(p<0.05) when evaluated by permutation. We also evaluated whether CNV burden was 
higher in cases than controls in the APOE ε4 negative participants. There was a similar 
trend toward a higher CNV call rate for deletions and lower CNV call rate for duplications 
in AD and MCI participants, but these were not statistically significant (p<0.05; data not 
shown). A large proportion of deletions and duplications were found in the 0.1-0.5 Mb 
size range (Table 6). Two AD participants were found to have very large CNV calls (>2 
Mb) (Figures 4 and 5). One AD participant had a deletion on chromosome 4 (Figure 4), 
which includes the following genes: NDST4 (N-deacetylase/N-sulfotransferase 4), 
TRAM1L1 (translocation-associated membrane protein 1-like 1), and MIR1973 
(microRNA 1973). The other AD participant had a duplication on chromosome 11 (Figure 
5), which includes the gene LUZP2 (leucine zipper protein 2). 
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Table 4. Sample demographics of participants in the ADNI cohort. 
 
Current diagnosis Alzheimer’s 
disease 
Mild cognitive 
impairment 
Healthy 
controls 
p value 
Number of 
participants 
222 136 143 - 
Gender 
(Males/Females) 
133/89 87/49 82/61 not significant 
Baseline age 
(Mean±SD) 
75.10±7.27 75.88±7.17 75.83±5.32 not significant 
Years of education 
(Mean±SD) 
15.30±3.05 15.85±3.01 16.24±2.62 0.009 
APOE group (ε4 
negative/ε4 positive) 
73/149 70/66 108/35 <0.001 
Age at onset 
(Mean±SD) 
74.08±7.73 - - - 
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Table 5. Characteristics of copy number variation calls in the three diagnostic 
groups from participants in the ADNI cohort. CNV-Copy number variation. 
 
 Alzheimer’s 
disease (n=222) 
Mild cognitive 
impairment (n=136) 
Healthy controls 
(n=143) 
Deletions: 
Number of CNVs 
Rate per participant 
Average size (kb) 
 
2128 
9.59 
73.24 
 
1340 
9.85 
76.32 
 
1278 
8.94 
79.38 
Duplications: 
Number of CNVs 
Rate per participant 
Average size (kb) 
 
886 
3.99 
157.24 
 
498 
3.66 
154.06 
 
607 
4.24 
170.30 
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Table 6. Participants in the ADNI cohort grouped by copy number variation call 
size. Del-Deletions; Dup-Duplications. 
 
Call size Alzheimer’s disease 
(n=222) 
Mild cognitive impairment 
(n=136) 
Healthy controls 
(n=143) 
 Del 
n (%) 
Dup 
n (%) 
Del 
n (%) 
Dup 
n (%) 
Del 
n (%) 
Dup 
n (%) 
0.1-0.5 Mb 174 
(78.38) 
183 (82.43) 104 
(76.47) 
100 (73.53) 114 
(79.72) 
120 (83.92) 
0.5-1.0 Mb 6 (2.70) 27 (12.16) 8 (5.88) 18 (13.24) 8 (5.94) 27 (18.88) 
1.0-1.5 Mb 0 (0.00) 8 (3.60) 0 (0.00) 4 (2.94) 2 (1.40) 8 (5.59) 
1.5-2.0 Mb 0 (0.00) 2 (0.90) 0 (0.00) 1 (0.74) 1 (0.70) 0 (0.00) 
>2.0 Mb 1 (0.45) 1 (0.45) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 
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Figure 4. Representative image of B Allele Frequency and Log R Ratio of the 
Alzheimer's disease participant in the ADNI cohort who had a deletion >2 Mb on 
chromosome 4. The orange shaded portion indicates the deleted region (Human 
Genome Build 36.1). 
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Figure 5. Representative image of B Allele Frequency and Log R Ratio of the 
Alzheimer's disease participant in the ADNI cohort who had a duplication >2 Mb 
on chromosome 11. The purple shaded portion indicates the duplicated region (Human 
Genome Build 36.1). 
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2. Case/control association analyses 
 
2.1. Candidate gene approach 
 
We identified regions overlapping 294 AD candidate genes with CNV calls from at least 
one case (AD and/or MCI) but no controls (HC). As expected, cell sizes were very small 
in each group leading to low power. Resulting CNV calls along with APOE genotype and 
age at onset (for the AD at baseline group) are presented in Table 7 for reference 
although these did not meet conventional significance (p<0.05). A number of genes, 
such as CHRFAM7A (CHRNA7 (cholinergic receptor, nicotinic, alpha 7, exons 5-10) and 
FAM7A (family with sequence similarity 7A, exons A-E) fusion), had CNV calls from only 
AD or MCI participants partially overlapping them. Figure 6 shows representative plots of 
two of these genes (CHRFAM7A and LRRTM3). 
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Table 7. Genes that had copy number variation calls from at least one Alzheimer’s 
disease and/or one mild cognitive impairment participant and no healthy controls 
in the ADNI cohort using the candidate gene approach. AD-Alzheimer’s disease; 
Chr-Chromosome; MCI-Mild cognitive impairment; N/A-Not available; aAge at onset of 
AD symptoms, available only for participants with a baseline diagnosis of AD; bThe same 
participant had CNV calls overlapping the two genes. 
 
Chr Region Start (bp) End (bp) AD (n) APOE 
status 
Age at 
onseta 
MCI 
(n) 
APOE 
status 
5 PPP2R2B 145949260 146441226 1 ε3/ε3 N/A 0 - 
6 ATXN1 16407321 16869700 1 ε3/ε4 83 years 0 - 
7 MAGI2 77484309 78920826 1 ε2/ε4 N/A 0 - 
7 RELN 102899472 103417198 0 - - 1 ε4/ε4 
9 GRIN3A 103371455 103540683 1 ε3/ε3 74 years 0 - 
10 LRRTM3 68355797 68530873 1 ε3/ε3 55 years 0 - 
10 LIPA 90963305 91001640 0 - - 1b ε3/ε3 
12 PPM1H 61324030 61614932 1 ε2/ε3 N/A 1 ε2/ε3 
15 CHRFAM7A 28440734 28473156 2 ε3/ε3 
ε3/ε4 
N/A 
N/A 
2 ε3/ε3 
ε3/ε4 
15 ADAM10 56675801 56829469 1 ε3/ε3 N/A 1b ε3/ε3 
21 DNAJC28 33782107 33785893 1 ε3/ε4 74 years 0 - 
21 DOPEY2 36458708 36588442 0 - - 1 ε3/ε4 
22 GSTT1 22706138 22714284 1 ε3/ε3 59 years 0 - 
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2.2. Whole genome approach 
 
We also identified CNV calls present in cases (AD and/or MCI) but not controls (HC) 
within regions overlapping 17938 genes. There was no significant (p<0.05) gene after 
correction for multiple testing. We, therefore, focused on genes that had an uncorrected 
p<0.05. The genes identified included CSMD1 (CUB and Sushi multiple domains 1), 
HNRNPCL1 (heterogeneous nuclear ribonucleoprotein C-like 1), and SLC35F2 (solute 
carrier family 35, member F2) (Table 8). We also observed CNVs overlapping two genes 
associated with neuropsychiatric disorders: NRXN1 (neurexin 1) [85, 91] and ERBB4 (v-
erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)) [143], but these did not 
reach significance (p<0.05). An MCI participant, who subsequently converted to clinical 
AD, was also observed to have a duplication comprising 23 genes in the 16p11.2 region 
(Figure 7). 
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Table 8. Significant (uncorrected p<0.05, relative to healthy controls) genes 
present in either Alzheimer's disease and/or mild cognitive impairment 
participants, but not healthy controls in the ADNI cohort using the whole genome 
approach. AD-Alzheimer's disease; Chr-Chromosome; MCI-Mild cognitive impairment. 
 
Chr Region Start (bp) End (bp) AD calls 
(n) 
AD calls 
(p value) 
MCI 
calls (n) 
MCI calls 
(p value) 
8 CSMD1 2780281 4839736 9 0.0114 4 0.0556 
1 HNRNPCL1 12829847 12831165 6 0.0493 4 0.0549 
11 SLC35F2 107166926 107234864 5 0.0820 6 0.0120 
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Figure 6. Candidate genes CHRFAM7A (A) and LRRTM3 (B), overlapped by copy 
number variation calls from at least one Alzheimer's disease and/or mild cognitive 
impairment participant, but no healthy controls in the ADNI cohort. The red 
rectangles represent deletions, and the blue rectangles represent duplications (March 
2006 (NCBI36/hg18) assembly). 
 
 
      A 
 
 
      B  
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Figure 7. Representative image of B Allele Frequency and Log R Ratio of the 
participant in the ADNI cohort who had a duplication at 16p11.2. The purple shaded 
portion indicates the duplicated region (Human Genome Build 36.1). 
 
 
  
59 
D. Discussion 
 
The present report represents an initial analysis of CNVs in the ADNI dataset and is the 
first CNV analysis of participants with MCI. After extensive QC, we analyzed CNV calls 
generated in cases (AD and MCI) compared to controls (HC), using whole genome and 
candidate gene association approaches. 
 
Comparison of the CNV calls between the three diagnostic groups showed no excess 
CNV burden (rate of calls) in AD and MCI participants compared to controls. This is 
consistent with previously published results [26]. Two AD participants were found to 
have CNV calls >2Mb. One AD participant had a duplication on chromosome 11 (Figure 
5) which includes the gene LUZP2 (leucine zipper protein 2). This gene has been shown 
to be expressed only in the brain and spinal cord in adult mouse tissues [144]. The 
authors of this study also found this gene to be deleted in some participants with Wilms 
tumor-aniridia-genitourinary anomalies-mental retardation syndrome. Another AD 
participant had a deletion on chromosome 4 (Figure 4), which includes the following 
genes: NDST4 (N-deacetylase/N-sulfotransferase 4), TRAM1L1 (translocation-
associated membrane protein 1-like 1), and MIR1973 (microRNA 1973). None of these 
genes have been previously associated with AD susceptibility. Further investigation by 
either cytogenetic techniques such as fluorescence in situ hybridization or molecular 
biology techniques such as quantitative real-time polymerase chain reaction (qPCR) and 
deep resequencing is required to determine the clinical relevance of these regions. 
 
A case/control association analysis was then performed using a candidate gene 
approach and a whole genome approach to determine if there was an excess of CNV 
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calls partially overlapping genes in AD or MCI participants relative to controls, 
suggesting potential involvement of these genes in AD or MCI susceptibility. 
 
The candidate gene approach revealed several interesting genes (Table 7 and Figure 6). 
The CHRFAM7A gene had CNV calls in cases (two AD and two MCI) but not in controls. 
CHRFAM7A, located on chromosome 15, consists of a partial duplication of the 
CHRNA7 (cholinergic receptor, nicotinic, alpha 7) gene (exons 5-10) fused to a copy of 
the FAM7A (family with sequence similarity 7A) gene (exons A-E) [145]. The 
CHRFAM7A gene contains a polymorphism consisting of a 2-bp deletion at position 497-
498 of exon 6. This 2-bp polymorphism has been associated with schizophrenia [146]. 
The CHRFAM7A genotype without the 2-bp allele has also been shown to be 
significantly over-represented in AD (p=0.011), dementia with Lewy bodies (p=0.001), 
and Pick’s disease (p<0.0001) participants [147]. 
 
Heinzen et al. (2010) found a duplication in six out of 276 dementia cases (2%) and one 
out of 322 controls (0.3%) within the schizophrenia and epilepsy-associated risk region 
at 15q13.3, affecting the CHRNA7 gene [26]. In the present study, we found a deletion in 
one out of 222 AD participants (0.45%) and one out of 136 MCI participants (0.74%), as 
well as a duplication in two out of 143 HC participants (1.40%). This gene codes for one 
of several neuronal cholinergic nicotinic receptors. Genetic variants in CHRNA7 and 
other cholinergic receptor genes have been implicated in AD susceptibility [26], and 
further investigation of this gene family is warranted. The number of CNV calls 
overlapping the identified genes is small, as we had a small sample size (n=501) after 
QC for analysis limiting power. Nevertheless, all identified genes have been previously 
investigated in AD studies and thus represent potential candidate genes. Replication 
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studies with larger sample sizes as well as laboratory validation are required to confirm 
the role of these genes in AD susceptibility. 
 
The whole genome approach revealed three genes at uncorrected p<0.05, as shown in 
Table 8. CSMD1 (CUB and Sushi multiple domains 1) has been shown to be primarily 
synthesized in the developing central nervous system and epithelial tissues [148]. It is 
enriched in the nerve growth cone, suggesting that it may be an important regulator of 
complement activation and inflammation in the developing central nervous system. 
HNRNPCL1 (heterogeneous nuclear ribonucleoprotein C-like 1) is predicted to play a 
role in nucleosome assembly by neutralizing basic proteins such as A and B core 
hnRNPs (Uniprot: http://www.uniprot.org/). SLC35F2 (solute carrier family 35, member 
F2), also known as lung squamous cell cancer-related protein LSCC-3, is integral to 
membrane and transport (Gene Ontology: http://www.geneontology.org/). 
 
We also identified CNVs overlapping two candidate genes associated with 
neuropsychiatric disorders: NRXN1 and ERBB4, from the whole genome approach in 
cases, but not in controls. Deletions in the NRXN1 (neurexin 1) gene were observed in 
four AD participants and three MCI participants; deletions in the ERBB4 (v-erb-a 
erythroblastic leukemia viral oncogene homolog 4 (avian)) gene were observed in four 
AD participants and one MCI participant, respectively. NRXN1, a member of the 
neurexin family on chromosome 2, is a cell surface receptor than binds neuroligins. The 
Ca2+-dependent neurexin-neuroligin complex is present in the central nervous system at 
synapses and is required for efficient neurotransmission and formation of synaptic 
contacts [149]. This gene has been found to have reduced expression with AD severity 
[150], and its disruption has been shown to be associated with schizophrenia [91, 119, 
140] and autism [85, 98]. Deletions in this gene have also been shown to predispose to 
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a variety of developmental disorders including autism spectrum disorders, language 
delays, and mental retardation [151]. Interestingly, an SNP (rs6463843) flanking the 
NXPH1 (neurexophilin 1) gene was identified by our group in a GWAS of neuroimaging 
phenotypes in the ADNI cohort [152]. The NXPH1 gene, a member of the neurexophilin 
family, forms a tight complex with alpha neurexins, and the SNP was found to be 
associated with reduced global and regional grey matter density. The ERBB4 gene, also 
on chromosome 2, is a member of the type I receptor kinase subfamily, that encodes a 
receptor for neuregulin 1 (NRG1). The neuregulin-ErbB receptor signaling pathway plays 
a role in development, synaptic function, and neural network activity and has been 
implicated in schizophrenia [153]. One AD participant had a large duplication that 
included 23 genes in the 16p11.2 region (Figure 7). CNVs in this region have previously 
been associated with autism [86, 94, 95], schizophrenia [154], cognitive impairment and 
speech/language delay [155], and obesity [156, 157], but not AD or MCI. Because the 
ADNI employed a case/control design, DNA from family members was not available for 
linkage analysis. This limitation precluded determination as to whether CNVs were de 
novo or inherited. 
 
The ADNI cohort provides a unique opportunity for discovery analyses such as this initial 
CNV analysis. With multiple types of potential biomarkers, including structural and 
molecular imaging, blood and cerebrospinal fluid markers, genetic information and 
behavioral data, analysis of the ADNI data has the potential to enhance knowledge of 
the underlying mechanisms leading to MCI and to AD. 
 
The present study has several limitations related to participant inclusion and exclusion 
and the software and algorithms used in the analyses. CNV calls in the present study 
were generated from DNA samples derived only from peripheral blood-78 participants 
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whose DNAs were derived from lymphoblastoid cell lines were excluded. 
Lymphoblastoid cell lines are generated by transforming peripheral B lymphocytes by 
the Epstein-Barr virus. Epstein-Barr virus-transformed cells are shown to have significant 
telomerase activity and develop aneuploidy, along with other cellular changes such as 
gene mutations and reprogramming in the postimmortal cellular stage of transformation 
[136]. Thus, to avoid CNV call discrepancies that may arise between the different DNA 
sources, we chose to include only those participants whose DNA was derived from 
peripheral blood. Additional QC was also performed, resulting in only 501 samples that 
passed all QC checks. To date, no definitive QC criterion has been established to 
ensure only high-quality samples are included in the CNV analyses. Therefore, the QC 
criterion applied in the present study may have been too stringent leading to the 
exclusion of samples which otherwise may have had informative CNV data. In future 
studies, we propose to analyze multiple QC thresholds to determine the optimum QC 
criteria. 
 
Another limitation is that the CNV calls analyzed in the current study were generated 
using only one software program (PennCNV). Several detection algorithms including 
HMMs, segmentation algorithms, t-tests, and SD of the LRR are available for identifying 
CNVs from genome-wide SNP array data. A comparison of these methods has been 
performed by Dellinger et al. (2010). Even though the PennCNV program was found to 
have moderate power in detecting CNVs, it also had a low false positive call rate. The 
program was found to detect less CNV calls in comparison to other methods and did not 
accurately detect small CNVs (3-4 SNP CNVs) [70]. However, in our analyses, we have 
included CNV calls that had at least 10 SNPs. Obtaining the same CNV calls from 
another algorithm would help further reduce false positive CNV calls. 
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The heterogeneity of the MCI group of participants also represents a possible limitation 
of the present study. Although biomarkers such as cerebrospinal fluid and Pittsburgh 
Compound-B-PET can help differentiate MCI participants who have an AD-like profile 
from those who have a normal profile, this data was only available for a small number of 
ADNI-1 participants which would have limited power to detect differences in CNVs. In 
the next phases of the project (ADNI-GO and ADNI-2), all subjects will have 
cerebrospinal fluid and amyloid PET data, enabling further examination of this issue. 
 
In sum, we have conducted an initial CNV analysis in the ADNI cohort dataset. Although 
no excess CNV burden was found in cases relative to controls, a number of interesting 
candidate genes and regions were identified. Replication in larger samples will be critical 
to confirm these findings. Additional region-based analyses may help elucidate the role 
of these CNVs, and deep resequencing studies may be warranted for some of these 
regions if they replicate in other cohorts.  
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III. Analysis of Copy Number Variation in Alzheimer's Disease: the NIA-
LOAD/NCRAD Family Study 
 
A. Introduction 
 
Alzheimer’s disease (AD) is the most common form of dementia characterized by loss of 
memory and other intellectual abilities, which eventually disrupts daily life activities. An 
estimated 5.4 million Americans have AD, the sixth leading cause of death across all 
ages in the United States [1]. The hallmark abnormalities of AD are deposits of the beta-
amyloid protein fragments (amyloid plaques) and twisted strands of the tau protein 
(neurofibrillary tangles). Although no current treatments can slow or halt its progression, 
a large research effort is being undertaken to identify causes that can lead to earlier 
diagnosis and treatment. Amnestic mild cognitive impairment (MCI) is a clinical condition 
in which a person has memory problems that are not normal for the individual’s age, but 
not severe enough to interfere significantly with daily functioning. Approximately 14-18% 
of individuals aged 70 years and older have MCI, and 10-15% of these individuals with 
MCI will likely progress to AD or another dementia every year [2]. 
 
Genetic variation is a key factor in the development and progression of AD, with 
approximately 58-79% of phenotypic variation estimated to be caused by genetic factors 
[4]. Early-onset AD (onset earlier than 60 or 65 years), which accounts for one to six 
percent of AD cases is caused by mutations in the APP, PSEN1 and PSEN2 genes. The 
leading genetic risk factor for the more common late-onset form of AD (onset later than 
60 or 65 years) is the APOE ε4 allele [158]. A member of a three allele haplotype 
(composed of ε2, ε3 and ε4 alleles), the ε4 allele shows a dose-dependent increase in 
AD risk of approximately four-fold in carriers as compared to noncarriers [9-11]. 
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Recently, other AD risk loci have been identified and replicated including: CLU, CR1, 
PICALM, BIN1, EXOC3L2, MTHFD1L, MS4A4A/MS4A6E, CD2AP, CD33, ABCA7 and 
CUGBP2 [12-19]. However, these loci do not account for all of the genetic variation 
associated with AD, and it is likely that other forms of genetic variation such as copy 
number variations (CNVs) play a role. 
 
CNVs are DNA regions ranging in size from one kilobase (kb) to several megabases 
(Mb) present in variable number of copies in the genome. The regions can have addition 
of genetic material (copy number gains or duplications) or loss of genetic material (copy 
number losses or deletions). They often overlap one or more genes, and may affect 
gene function [34]. At the time of performing this work, only four studies have 
investigated the role of CNVs in late-onset AD [26, 129, 130, 159]. Heinzen et al. (2010) 
performed a case-control genome-wide scan of AD and identified a duplication in the 
CHRNA7 gene that they thought warranted further investigation [26]. In an in-depth 
analysis of the CR1 region, Brouwers et al. (2011) observed a low-copy repeat 
associated CNV in CR1, that produced different CR1 isoforms, CR1-F and CR1-S [129]. 
They were able to obtain a significant association in carriers of CR1-S with AD and were 
able to replicate this finding in an independent cohort. In a case-only genome-wide CNV 
association study, Shaw et al. (2011) demonstrated that a chromosomal region on 
14q11.2, encompassing a cluster of olfactory receptors, is associated with age at onset 
of AD [130]. 
 
In a previous study, we performed a case-control CNV analysis in 288 AD, 183 MCI, and 
184 control non-Hispanic Caucasian participants in the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) study who had DNA samples derived from peripheral 
blood (described in Chapter II and [159]). The analyses included candidate gene and 
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genome-wide approaches to identify genes overlapped by CNVs only in cases (AD 
and/or MCI) but not in controls. Although no excess CNV burden was observed in cases 
compared to controls, CNVs overlapping the candidate gene CHRFAM7A, as well as 
CSMD1, SLC35F2, HNRNPCL1, NRXN1, and ERBB4 regions were identified only in 
cases. Using a similar approach, we analyzed the role of CNVs in AD using unrelated 
non-Hispanic Caucasian participants in the National Institute of Aging-Late Onset 
AD/National Cell Repository for AD (NIA-LOAD/NCRAD) Family Study [19] who had 
DNA samples derived from blood or brain tissue. Case/control association analyses 
were performed to compare the CNV burden between AD participants (cases) and 
controls, and to characterize genomic regions where CNVs were detected in cases but 
not in controls. 
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B. Methods 
 
Data used in this study were obtained from the "NIA-Late Onset Alzheimer's Disease 
and National Cell Repository for Alzheimer's Disease Family Study: Genome-Wide 
Association Study for Susceptibility Loci" dataset (dbGaP Study Accession: 
phs000168.v1.p1, Project #2026) on the database of Genotypes and Phenotypes 
(dbGaP; http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000168.v1.p1) website. 
 
1. Participants 
 
Recruitment information for participants in the NIA-LOAD Family Study and NCRAD has 
been previously described [19]. Briefly, the AD sample contained individuals from 
families as well as unrelated individuals who had a family history of AD. All individuals 
were recruited after providing informed consent and with approval by the relevant 
institutional review boards. The study was conducted according to the principles in the 
Declaration of Helsinki. The dataset contained information for 607 families (1516 
affected, 1306 unaffected) from the NIA-LOAD Family Study, 138 families (337 affected, 
166 unknown intermediate phenotypes) from NCRAD, and 471 unrelated patients from 
the NIA-LOAD Family Study and NCRAD. Three sources were used to ascertain 
unrelated controls: the NIA-LOAD Family Study (n=794), and NCRAD (n=144), with the 
NCRAD controls including 141 participants from the University of Kentucky. The NIA-
LOAD and NCRAD recruited controls did not have a family history of late-onset AD in a 
first degree relative, whereas the University of Kentucky controls were not excluded if 
they had a family history of late-onset AD. Genome-wide genotyping for all samples was 
performed at the Center for Inherited Disease Research (http://www.cidr.jhmi.edu/) using 
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the Illumina Human610-Quad BeadChip. The APOE polymorphisms (based on rs7412 
and rs429358) for all samples were genotyped at PreventionGenetics 
(http://www.preventiongenetics.com/). The phenotype and genotype information for all 
participants were available as part of the dataset. 
 
2. Alzheimer's Disease Neuroimaging Initiative 
 
The ADNI data used in the present study was obtained from the ADNI database 
(http://adni.loni.ucla.edu). Launched in 2003 as a $60 million, multiyear public-private 
partnership, the primary goal of ADNI has been to test whether serial magnetic 
resonance imaging, positron emission tomography, other biological markers, and clinical 
and neuropsychological assessments can be combined to measure the progression of 
MCI and early AD. Michael W. Weiner, MD, VA Medical Center and University of 
California-San Francisco is the Principal Investigator of this initiative. Further information 
about ADNI can be found at http://www.adni-info.org. Genome-wide genotyping of the 
ADNI sample was performed using the Illumina Human610-Quad BeadChip as 
previously described [137, 159]. The APOE polymorphisms (rs429358 and rs7412) were 
genotyped separately. Clinical, imaging, biomarker and genetic information for all ADNI 
participants is available in the ADNI database. 
 
3. Sample selection criteria 
 
For the present analysis, we selected unrelated AD participants (n=794) and controls 
(n=196) of non-Hispanic Caucasian descent who had DNA samples extracted from 
blood or brain tissue as described below. 
 
70 
3.1. Genotype data 
 
Genotype data for 5573 participants were available as part of this dataset. Participants 
who had DNA samples extracted from "Blood" or "Brain Tissue" were selected for the 
present analyses. Those with DNA samples extracted from lymphoblastoid cell lines 
were excluded because cell line transformation may bias CNV results [135, 136]. Also, 
only samples that were determined to have "High Quality Genotyping Data; High Quality 
Intensity Data for CNV detection" or "High Quality Genotyping Data; Low Quality 
Intensity Data for CNV detection" in order to have maximum power and 
representativeness and no known chromosomal abnormality were included in the 
analyses. 2843 samples with genotype data were available after these filtering steps. 
 
3.2. Phenotype data 
 
Phenotype data for 5220 participants were available as part of this dataset. Participants 
with a diagnosis of "Alzheimer disease" (AD) or "Neurologically evaluated control" 
(controls) were selected for the analyses. An AD participant was defined as an individual 
meeting the National Institute of Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria for 
probable or possible AD [160], or meeting NINCDS-ADRDA criteria for definite AD when 
clinical and pathological information was available, or the Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) pathological criteria [161] for AD based on 
postmortem information alone. A control was defined as an individual who demonstrated 
or had a documented history of normal cognitive function for age. Controls were 
determined by clinical or neuropathological examination to not meet criteria for AD. Only 
participants who were “recruited as controls” and not part of an AD family were selected 
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as controls. We also restricted our analyses to non-Hispanic Caucasian participants 
identified from principal component analyses using the smartpca program from the 
EIGENSOFT package [162]. 2761 participants (1852 AD and 909 controls) with 
phenotype data remained after these filtering steps. 1592 participants (1312 AD and 280 
controls) had both genotype and phenotype data. 
 
3.3. Selection of one participant per family 
 
One AD participant per family was selected based on the following criteria: (1) diagnosis 
level (definite AD>probable AD>possible AD); (2) lower age of dementia symptoms; (3) 
lower age at which participant was diagnosed with AD; and (4) higher genotype call rate. 
One control per family was selected based on a higher genotype call rate. Controls were 
not biologically related to the portions of the family affected by AD. 795 cases and 249 
controls remained after this filtering step. Although controls with no family history of AD 
were recruited, over time they may have family members develop AD. 54 such recruited 
controls (53 controls and one control who converted to AD) had first degree relatives 
with AD, and were excluded from the analyses. After all filtering steps, 990 participants 
(794 AD and 196 controls) were available for performing the case/control association 
analyses. 
 
4. Generation of copy number variation calls and quality control 
 
CNV call generation and quality control (QC) measures in the present study were 
performed as described in a previous similar study, Swaminathan et al. (2011) [159]. 
Briefly, the Log R Ratio (LRR) and B Allele Frequency (BAF) values for each sample 
were used for the generation of CNV calls for the sample. The LRR of a sample is the 
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log (base 2) ratio of the normalized intensity value for the SNP divided by the expected 
normalized intensity value. The BAF for a sample is the allelic composition (copy angle) 
for a SNP that is corrected for cluster position. A large set of normal individuals were 
used to generate the cluster positions (Illumina GenomeStudio Genotyping Module v1.0 
User Guide). PennCNV software (2010Jun22 version) 
(http://www.openbioinformatics.org/penncnv/) [68], which implements a Hidden Markov 
model (HMM) was used for the generation of CNV calls. A number of detection 
algorithms are available for analyzing CNVs from genome-wide SNP array data 
including HMM, segmentation algorithms, t-tests and standard deviations (SDs) of the 
LRR. A comparison of these methods has been performed by Dellinger et al. (2010) [70]. 
Although the PennCNV program was observed to have moderate power in detecting 
CNVs, it also had a low false positive call rate and hence was used for the generation of 
CNV calls. A genomic wave adjustment procedure [138] as implemented in PennCNV 
was carried out. A frequency distribution plot of the number of CNV calls for all samples 
was made, and a sample was excluded if the number of CNV calls for the sample was 
greater than the 90th percentile. Samples were also excluded if: LRR SD>0.35, BAF 
Drift>0.002 or Waviness Factor>0.04. An AD sample was observed to have a very large 
(~11.5 Mb) deletion on chromosome 14 and was excluded from the analyses as it may 
be a possible outlier. Due to complications of hemizygosity in males and X-chromosome 
inactivation in females, we restricted our analyses to autosomes. To ensure only high 
quality samples were included in the analyses, CNVs for which the difference of the 
most likely copy number state and less likely copy number state was less than 10, CNV 
calls generated based on data from less than 10 SNPs, and CNVs that had >50% 
overlap with centromeric, telomeric, and immunoglobulin regions as defined in Need et 
al. (2009) [140] were excluded. 882 participants (711 AD, 171 controls) with 8211 CNV 
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calls remained after all QC measures and were entered into the case/control association 
analyses. 
 
5. Case/control association analyses 
 
Case/control association analyses were performed using CNV calls generated for the 
AD participants and controls using PLINK v1.07 
(http://pngu.mgh.harvard.edu/~purcell/plink/) [141] to determine CNV call differences 
between cases (AD) and controls. As in the ADNI study, two approaches were used: (1) 
a candidate gene approach consisting of AD genes identified from the AlzGene 
database (Updated 5 January 2011) (http://www.alzgene.org/) [8] as having a positive 
association with AD in at least one study, consisting of 317 genes tested, and (2) a 
genome-wide approach using PLINK's gene list (hg18 coordinates), consisting of 17938 
genes tested. We also performed the candidate gene analysis in the ADNI study using 
the same AD candidate gene list as used in the present study to compare the results 
obtained in the two studies. The AlzGene database is a publicly available and regularly 
updated online resource that comprehensively catalogs genetic case/control and family 
association studies in AD. In both approaches, CNV segments either partially or 
completely overlapping gene regions were analyzed, and both deletions and duplications 
were included in the analyses. 
 
Representative plots of the CNV calls (Figure 10) were created in UCSC Genome 
Browser (http://genome.ucsc.edu/) [142] (March 2006 (NCBI36/hg18) assembly). The 
Genome Browser track for the Illumina Human-610 array was obtained from the 
PennCNV website 
(http://www.openbioinformatics.org/penncnv/penncnv_download.html). The Illumina 
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Genome Viewer plug-in (Human Build 36.1) within GenomeStudio was used to generate 
representative plots of LRR and BAF values for the participants (Figures 8, 9, 11 and 
12). 
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C. Results 
 
1. Sample demographics and copy number variation call characteristics 
 
The sample demographics of the 882 participants (711 AD and 171 controls) are shown 
in Table 9. Of the 711 AD participants, 263 participants had a diagnosis of definite AD, 
425 participants had a diagnosis of probable AD, and 23 participants had a diagnosis of 
possible AD. Significant (p<0.05; two-sided) differences in the number of years of 
education, the absence or presence of the APOE ε4 allele and the DNA source were 
observed between the AD participants and controls. The CNV call characteristics of the 
882 participants are shown in Table 10. 
 
8211 CNV calls (5586 deletions and 2625 duplications) were observed with an average 
CNV call length of 87.07 kb and an average of 26 SNPs per CNV call. A higher CNV call 
rate and a lower average CNV call size were observed in deletions compared to 
duplications. A trend towards a lower CNV call rate was observed for deletions as well 
as for duplications in AD participants compared to controls, but this was not significant 
(p>0.05; two-sided) when evaluated by permutation. The largest proportion of deletions 
and duplications were found in the 0.1-0.5 Mb range (Table 11). Two AD participants 
were observed to have very large CNV calls (>2 Mb) (Figures 8 and 9). The first AD 
participant had a 2.4 Mb deletion on chromosome 11 (Figure 8), which includes many 
genes. The second AD participant had a 3.2 Mb duplication on chromosome 3 (Figure 
9), which includes the GBE1 gene. 
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Table 9. Sample demographics of participants in the NIA-LOAD/NCRAD Family 
Study cohort. 
 
 Alzheimer's disease Controls p (two-sided) 
Number of participants 711 171 - 
Gender (Males/Females) 243/468 (n=711) 72/99 (n=171) 0.052 
Years of education 
(Mean±SD) 
13.20±3.02 (n=364) 15.16±3.07 (n=160) <0.001 
APOE group (ε4 negative/ ε4 
positive) 
174/537 (n=711) 136/35 (n=171) <0.001 
Age at last evaluation 
(Mean±SD) 
- 79.33±11.20 (n=171) - 
Age participant developed 
dementia symptoms 
(Mean±SD) 
72.02±6.77 (n=705) - - 
Age participant diagnosed 
with Alzheimer's disease 
(Mean±SD) 
75.85±6.88 (n=586) - - 
DNA Source (Blood/Brain 
Tissue) 
673/38 (n=711) 136/35 (n=171) <0.001 
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Table 10. Characteristics of copy number variation calls from participants in the 
NIA-LOAD/NCRAD Family Study cohort. CNV-Copy number variation. 
 
 Alzheimer's disease 
(n=711) 
Controls  
(n=171) 
Deletions Number of CNVs 4453 1133 
Rate per participant 6.26 6.63 
Average size (kb) 65.94 61.92 
Duplications Number of CNVs 2074 551 
Rate per participant 2.92 3.22 
Average size (kb) 133.1 124.4 
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Table 11. Participants in the NIA-LOAD/NCRAD Family Study cohort grouped by 
copy number variation call size. 
 
Call size Alzheimer's disease (n=711) Controls (n=171) 
 Deletions  
n (%) 
Duplications  
n (%) 
Deletions  
n (%) 
Duplications  
n (%) 
0.1-0.5 Mb 440 (61.88) 477 (67.09) 102 (59.65) 116 (67.84) 
0.5-1.0 Mb 12 (1.69) 39 (5.49) 4 (2.34) 12 (7.02) 
1.0-1.5 Mb 2 (0.28) 10 (1.41) 1 (0.58) 0 (0.00) 
1.5-2.0 Mb 3 (0.42) 4 (0.56) 0 (0.00) 0 (0.00) 
>2.0 Mb 1 (0.14) 1 (0.14) 0 (0.00) 0 (0.00) 
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Figure 8. Representative image of B Allele Frequency and Log R Ratio of the 
Alzheimer's disease participant in the NIA-LOAD/NCRAD Family Study cohort who 
had a deletion >2 Mb on chromosome 11 including chromosomal coordinates and 
the genes in the corresponding regions. Each blue dot in the B Allele Frequency and 
Log R Ratio plots represents a single nucleotide polymorphism. The orange shaded 
portion indicates the deleted region (Human Genome Build 36.1). 
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Figure 9. Representative image of B Allele Frequency and Log R Ratio of the 
Alzheimer's disease participant in the NIA-LOAD/NCRAD Family Study cohort who 
had a duplication >2 Mb on chromosome 3 including chromosomal coordinates 
and the genes in the corresponding regions. Each blue dot in the B Allele Frequency 
and Log R Ratio plots represents a single nucleotide polymorphism. The blue shaded 
portion indicates the duplicated region (Human Genome Build 36.1). 
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2. Case/control association analyses 
 
2.1. Candidate gene approach 
 
CNV calls overlapping 317 AD candidate genes from at least one case (AD) but no 
controls were identified. The 30 genes identified are presented in Table 12 for reference 
although these do not meet conventional significance (p<0.05; one-sided) due to low 
power. On performing a similar analysis using the same AD gene list in the ADNI study, 
15 genes were also identified as being overlapped by CNV calls from at least one case 
(AD and/or MCI) but no controls. Five genes were identified by both studies: ATXN1, 
HLA-DPB1, RELN, DOPEY2 and GSTT1. The conditional probability of five or more 
genes being simultaneously identified by the two studies was evaluated by combinatorial 
calculation (p=0.0083). The CHRFAM7A gene reported in the ADNI study [159] was also 
identified in 12 AD participants and one control in the present study (Figure 10). 
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Table 12. Genes overlapped by copy number variation calls from at least one 
Alzheimer’s disease participant and no controls in the NIA-LOAD/NCRAD Family 
Study cohort using the candidate gene approach. aGenes also identified in the 
Alzheimer’s Disease Neuroimaging Initiative Study as being overlapped by copy number 
variation calls in Alzheimer’s disease and/or mild cognitive impairment participants, but 
not controls; bOne Alzheimer's disease participant had copy number variation calls 
overlapping the two genes; cA different Alzheimer's disease participant had copy number 
variation calls overlapping the two genes. 
 
Chromosome Region Start (bp) End (bp) Number of Alzheimer’s 
disease participants 
1 CFH 194887630 194983257 1 
6 ATXN1a 16407321 16869700 3 
6 HLA-A 30018309 30021633 2 
6 MICA 31479349 31491069 4 
6 HLA-DQA1 32713160 32719407 5b 
6 HLA-DOA 33079937 33085367 1c 
6 HLA-DPB1a 33151737 33162954 1c 
7 CD36 80069439 80146529 1 
7 RELNa 102899472 103417198 1 
9 APBA1 71235021 71477042 4 
9 ABCA1 106583104 106730257 3 
9 RXRA 136358230 136472252 1 
10 ABCC2 101532452 101601652 1 
11 PICALM 85346132 85457756 1 
15 CYP19A1 49287545 49418087 1 
15 CHRNA3 76674705 76700377 1 
15 MEF2A 97956184 98071524 1 
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Chromosome Region Start (bp) End (bp) Number of Alzheimer’s 
disease participants 
17 TP53 7512444 7531588 1 
17 COX10 13913443 14052721 1 
17 SREBF1 17656110 17681050 3b 
17 CCL3 31439715 31441619 2 
17 KIF18B 40358973 40380608 1 
18 DSC1 26963211 26996817 1 
21 NCAM2 21292503 21833085 1 
21 APP 26174731 26465003 1 
21 DOPEY2a 36458708 36588442 2 
21 KCNJ6 37918656 38210566 2 
22 COMT 18309308 18336530 2 
22 BCR 21852551 21990224 1 
22 GSTT1a 22706138 22714284 1 
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2.2. Genome-wide approach 
 
We also identified CNV calls present in cases (AD) but not controls overlapping 17938 
genes in the human genome. The IMMP2L gene was identified in 13 AD participants 
although it did not reach conventional significance (uncorrected p=0.059; one-sided) 
(Figure 10). This gene was also found to be overlapped by CNV calls from four AD, one 
MCI and one control in the ADNI study. The CSMD1, HNRNPCL1 and SLC35F2 genes 
reported in the ADNI study were found to be overlapped by CNV calls from 11 AD 
participants and six controls, 23 AD participants and 11 controls, and 20 AD participants 
and three controls respectively from the NIA-LOAD/NCRAD sample. Two genes 
associated with neuropsychiatric disorders reported in the ADNI study: NRXN1 and 
ERBB4, were also identified in the present study in five and four AD participants, but not 
in controls. An AD participant was observed to have a duplication in the 16p13.11 region 
(Figure 11) and another AD participant was observed to have a deletion in the 17p12 
region (Figure 12). 
 
  
85 
Figure 10. Representative UCSC Genome Browser (March 2006 (NCBI36/hg18) 
assembly) plots of deletions overlapping the CHRFAM7A (A) and IMMP2L (B) 
genes in participants from the NIA-LOAD/NCRAD Family and ADNI studies. 
 
 
      A 
 
 
      B 
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Figure 11. Representative image of B Allele Frequency and Log R Ratio of the 
Alzheimer's disease participant in the NIA-LOAD/NCRAD Family Study cohort who 
had a duplication at 16p13.11 along with chromosomal coordinates and genes in 
corresponding regions are shown. Blue dots in the B Allele Frequency and Log R 
Ratio plots represent single nucleotide polymorphisms. The blue shaded portion 
indicates the duplicated region (Human Genome Build 36.1). 
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Figure 12. Representative image of B Allele Frequency and Log R Ratio of the 
Alzheimer's disease participant in the NIA-LOAD/NCRAD Family Study cohort who 
had a deletion at 17p12 along with chromosomal coordinates and genes in 
corresponding regions are shown. Blue dots in the B Allele Frequency and Log R 
Ratio plots represent single nucleotide polymorphisms. The orange shaded portion 
indicates the deleted region (Human Genome Build 36.1). 
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D. Discussion 
 
The present report represents an initial analysis of CNVs in the NIA-LOAD/NCRAD 
Family Study and a follow-up report and partial replication of the CNV analyses in the 
ADNI study. After extensive QC, we performed case (AD)/control association analyses 
using candidate gene and genome-wide approaches similar to those used in the ADNI 
study. 
 
Comparison of the CNV calls in the two diagnosis groups showed a trend towards a 
lower CNV call rate for deletions as well as duplications in AD participants compared to 
controls. In the ADNI study, a trend towards a higher CNV call rate for deletions and a 
lower CNV call rate for duplications in AD and MCI participants compared to controls 
was observed. The differences observed between the two studies may be due to 
random sampling variation, different participant selection criteria, and that the ADNI 
study analyses also included MCI participants in addition to AD participants and controls, 
whereas the NIA-LOAD/NCRAD Family Study analyses included only AD participants 
and controls. Two AD participants in the present study were identified as having very 
large CNV calls (>2 Mb) (Figures 8 and 9). The first AD participant had a 2.4 Mb deletion 
on chromosome 11 (Figure 8), overlapping a number of genes including olfactory 
receptor genes. Olfactory receptor genes are members of a large multigene family 
encoding signaling transduction pathway components involved in odorant discrimination 
[163]. Many of the olfactory receptor genes are located on chromosomes 6, 11 and 17, 
as well as distributed on other chromosomes. Odor identification has been shown to be 
impaired early in AD [164] and an increase in odor identification deficits has been shown 
in MCI participants compared to participants without MCI [165]. A high copy number in a 
region on chromosome 14 encompassing a cluster of olfactory receptors was recently 
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shown to be associated with younger age at onset of AD [130]. The second AD 
participant had a 3.2 Mb duplication on chromosome 3 (Figure 9), which includes the 
GBE1 (glucan (1,4-alpha-), branching enzyme 1) gene. The protein encoded by this 
gene is a glycogen branching enzyme involved in glycogen biosynthesis and mutations 
in the gene have been associated with glycogen storage disease IV [166]. This gene has 
not been previously associated with AD susceptibility. Further characterization of these 
regions by cytogenetic or molecular techniques is required to determine their clinical 
relevance. 
 
Case/control association analyses using a candidate gene approach and a genome-wide 
approach similar to those used in the ADNI study were performed. CNV calls partially 
overlapping genes in AD participants relative to controls were determined, suggesting a 
possible role for these genes in AD susceptibility. 
 
Several interesting genes were identified using a candidate gene approach (Table 12). 
The CHRFAM7A (CHRNA7 (cholinergic receptor, nicotinic, alpha 7, exons 5-10) and 
FAM7A (family with sequence similarity 7A, exons A-E) fusion) gene reported in the 
ADNI study was also identified in 12 AD participants and one control in the present study 
(Figure 10). Located on chromosome 15, the gene is a hybrid consisting of a partial 
duplication of the CHRNA7 gene fused to a copy of the FAM7A gene [145, 167]. It is 
highly polymorphic and individuals with and without the gene have been identified. A 2-
bp deletion polymorphism at position 497-498 in exon 6 of the gene has been associated 
with schizophrenia [146], and a significant over-representation of the CHRFAM7A 
genotype without the 2-bp allele has been observed in AD participants, dementia with 
Lewy bodies participants and Pick’s disease participants compared to controls [147]. 
Although CHRFAM7A is transcribed, its translation and the possible role of the resulting 
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protein is uncertain. Recently, de Lucas-Cerrillo et al. (2011) cloned and expressed the 
full-length coding sequence of the CHRFAM7A transcript in pituitary-derived GH4C1 
cells and oocytes [168]. On performing a functional study of the protein in oocytes, they 
observed a dominant negative regulatory function of the protein on α7 nicotinic 
acetylcholine receptors (α7 nAChRs) activity through reduction in the number of 
functional α7 nAChRs incorporated into the oocyte surface. Based on these and other 
results, they suggested that the CHRFAM7A gene product could possibly modulate α7 
subunit receptor-mediated synaptic transmission and cholinergic anti-inflammatory 
response. Another recent study by Araud et al. (2011) suggests CHRFAM7A to be a 
dominant negative modulator of CHRNA7 function and important for receptor regulation 
in humans [169]. In order to determine how α7 nAChR activation would affect APP 
processing, Nie et al. (2010) constructed a SH-EP1-α7 nAChR-hAPP695 cell line model 
co-expressing α7 nAChR gene and human amyloid precursor protein 695 (hAPP695) 
gene [170]. Their results demonstrated that, by regulating γ-secretase activity, activation 
of α7 nAChR reduced APP processing in the amyloidogenic pathway. At the same time, 
the activation was found to enhance APP processing in the non-amyloidogenic pathway, 
thus suggesting a role of α7 nAChR in APP processing. Although the identified genes 
were overlapped by a small number of CNV calls, these genes have been previously 
investigated in AD studies and thus represent potential candidate genes. The role of 
these genes in AD susceptibility can be confirmed by performing replication studies in 
other samples and laboratory validation. 
 
In order to compare NIA-LOAD/NCRAD results with those obtained in the previous ADNI 
study, we performed candidate gene analyses using the same AD gene list as the 
present study. Five genes (ATXN1, HLA-DPB1, RELN, DOPEY2 and GSTT1) identified 
in the NIA-LOAD/NCRAD Family Study were also identified in the ADNI study as being 
91 
overlapped by CNV calls from cases (AD and/or MCI participants), but not controls. The 
present study identified 30 genes and the ADNI study identified 15 genes. There was a 
statistically significant agreement (conditional probability, p=0.0083) for these five genes 
showing a signal across the two studies. The ATXN1 (ataxin 1) gene on chromosome 6 
encodes a protein ataxin-1, the mutated form of which is associated with spinocerebellar 
ataxia type 1. The loss of function of this gene has been shown to increase amyloid-beta 
40 and amyloid-beta 42 levels by potentiating beta-secretase processing of amyloid 
precursor protein [171]. ATXN1 and the related Brother of ATXN1 (BOAT1) have been 
recently shown to be important components of the Notch signaling pathway, and may 
play a role in several Notch-controlled development and disease processes [172]. An 
evidence of association has been suggested between an intronic SNP (rs179943) in this 
gene and AD [173]. The HLA-DPB1 (major histocompatibility complex, class II, DP beta 
1) also on chromosome 6 is a member of the human leukocyte antigen (HLA) class II 
beta chain paralogues and plays a major role in the immune system by presenting 
peptides derived from extracellular proteins. The HLA alleles have been previously 
investigated for association to AD [174, 175]. The RELN (reelin) gene on chromosome 7 
encodes for a large secreted extracellular matrix protein thought to control cell-cell 
interactions important during brain development for cell positioning and neuronal 
migration. Variants in the gene have been associated with AD [176]. Increased 
expression of reelin has been observed in the pyramidal neurons of the hippocampus in 
AD individuals and in cognitively intact controls with AD-associated pathology [177]. The 
authors of the study suggest that the reelin up-regulation may be a compensatory 
response to amyloid-beta or tau-related stress associated with AD even prior to the 
onset of dementia. The DOPEY2 (dopey family member 2) or C21orf5 gene located in 
the Down syndrome critical region on chromosome 21 has been considered a potential 
Down syndrome candidate gene [178]. The gene has been shown to be differentially 
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expressed and overexpressed in Down syndrome brains and it is thought that its 
overexpression could play an important role in the neurological phenotypes and mental 
retardation in Down syndrome patients. The GSTT1 (glutathione S-transferase theta 1) 
gene on chromosome 22 is a member of a protein superfamily that catalyses the 
conjugation of reduced glutathione to a number of electrophilic and hydrophobic 
compounds. Glutathione S-transferase variants have been previously investigated for 
association to AD [179, 180]. 
 
The genome-wide approach revealed CNV calls overlapping the IMMP2L (IMP2 inner 
mitochondrial membrane peptidase-like (S. cerevisiae)) gene in 13 AD participants, but 
no controls. This gene was also identified in four AD, three MCI and one control in the 
ADNI study (Figure 10). Located on chromosome 7, IMMP2L is a catalytic subunit of the 
mitochondrial inner membrane peptidase complex [181]. The mitochondrial inner 
membrane peptidase complex proteolytically removes the mitochondrial targeting 
presequence of nuclear-encoded proteins to generate mature, active proteins in the 
mitochondrial intermembrane space. IMMP2L was first identified in a patient with Gilles 
de la Tourette syndrome (TS) who carried a de novo inverted duplication of a segment of 
the long arm of chromosome 7 [182]. Recently, it has been identified as being disrupted 
in another patient with TS who had a de novo translocation between chromosomes 2 
and 7 [183]. Reverse-transcription polymerase chain reaction analyses showed 
ubiquitous expression of this gene except in the adult liver and lung. In mutant mice with 
a mutation in the IMMP2L gene, the mutation has been shown to affect the signal 
peptide sequence processing of mitochondrial proteins cytochrome c1 and glycerol 
phosphate dehydrogenase 2 [184]. This affected the mitochondrial function such that 
mitochondria from mutant mice generated higher than normal superoxide ion levels and 
there was impaired fertility in both sexes. Mutant mice have also been shown to manifest 
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multiple aging-associated phenotypes including wasting, loss of subcutaneous fat, 
sarcopenia, kyphosis and ataxia, and the loss of subcutaneous fat was due to impaired 
adipose progenitor/stem cells self-renewal [185]. The authors suggest that accelerated 
aging is driven by mitochondrial reactive oxygen species and that reactive oxygen 
species damage to adult stem cells could be a possible mechanism for age-associated 
disorders. The CSMD1 (CUB and Sushi multiple domains 1), HNRNPCL1 
(heterogeneous nuclear ribonucleoprotein C-like 1) and SLC35F2 (solute carrier family 
35, member F2) genes reported in the ADNI study were found to be overlapped by CNV 
calls from 11 AD participants and six controls, 23 AD participants and 11 controls, and 
20 AD participants and three controls respectively in the present study. None of these 
genes have been previously associated with AD. These genes warrant further 
investigation in independent samples to determine their role in AD susceptibility. 
 
Two neuropsychiatric disorder candidate genes: NRXN1 and ERBB4, reported in the 
ADNI study, were also identified in the present study to be overlapped by CNV calls only 
in AD participants, but not in controls. Deletions in four AD participants were observed in 
the NRXN1 (neurexin 1) gene; deletions in four AD participants and a duplication in one 
AD participant were observed in the ERBB4 (v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian)) gene. NRXN1 is a member of the neurexin family located 
on chromosome 2. Neurexins are molecules on the cell surface that form a heterophilic, 
Ca2+-dependent complex at central nervous system synapses by binding to neuroligins 
[149]. This transsynaptic complex is essential for formation of synaptic contacts and 
efficient neurotransmission. Although NRXN1 has not been previously associated with 
AD, the gene has been shown to have decreased expression with increasing AD 
severity [150]. The gene has also been associated with autism [85], autism spectrum 
disorders [98] and schizophrenia [91]. The ERBB4 gene, also located on chromosome 2, 
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belongs to the type I receptor tyrosine kinase subfamily, and encodes a receptor for 
neuregulin 1 (NRG1). It is widely expressed in many adult and fetal tissues, with high 
levels of expression observed in the developing brain and heart [186]. NRG1 and ErbB4 
immunoreactivity have been found to be associated with neuronal plaques in AD brains 
as well in a transgenic mouse model of AD [187]. A significant increase in ErbB4 
immunoreactivity was also observed in AD human brains, and this was demonstrated to 
colocalize with the apoptotic signal Bax in apoptotic hippocampal pyramidal neurons, 
suggesting the possible role of NRG1/ErbB4 signaling as a survival signal in AD 
progression [188]. The authors in a more recent study showed that the 
immunoreactivities of ErbB4 and phospho-ErbB4 were of higher intensity in the neurons 
of the CA1-2 transitional field of AD brains compared to age-matched controls [189]. 
They also observed an increased ErbB4 expression in the neurons of the cortico medial 
nucleus amygdala, human basal forebrain and superior frontal gyrus of AD brains. 
ErbB4 immunoreactivity was also found to be significantly increased in the cerebral 
cortex and hippocampus of amyloid precursor protein/presenilin 1 double transgenic 
mice compared to age-matched wild type control. The authors thus suggested that 
ErbB4 immunoreactivity upregulation may be involved in the progression of AD 
pathology. An AD participant was observed to have a duplication in the 16p13.11 region 
(Figure 11). Duplications at 16p13.11 have been observed to be significantly enriched in 
individuals with neurocognitive disease [190], attention-deficit hyperactivity disorder 
[191] and schizophrenia [92] compared to controls, but have not been previously 
associated with AD. A different AD participant was observed to have a deletion in the 
17p12 region (Figure 12). Although this region is a possible schizophrenia candidate loci 
[116, 192], it has not been previously associated with AD. 
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A number of gene regions overlapped by CNV calls were identified in the present study. 
Molecular characterization of these regions will be required to determine their specific 
mechanistic relevance in normal aging and AD. With further study, some of these 
regions may hold promise for biomarker or drug target development. 
 
The present study has some limitations regarding the selection criteria chosen for the 
analysis as mentioned in the Methods section. We excluded any controls that were 
biologically related to individuals with AD as it was possible that these participants could 
develop AD at a later time, and might have shared genetic regions with the affected 
family members. Thus, a higher number of AD participants (n=794) compared to controls 
(n=196) were included in the present study. Also, it has been shown that Epstein-Barr 
virus-transformed peripheral B lymphocytes, in the postimmortal stage, develop strong 
telomerase activity and aneuploidy, as well as gene mutations and reprogramming [136]. 
These changes may lead to biological artifacts [135, 193], and hence we chose to 
include only participants whose DNA samples were derived from blood or brain tissue. 
There does not yet appear to be a well-defined consensus set of QC criteria to ensure 
that the most appropriate samples are included in CNV analyses. Thus, it is possible that 
the QC measures used in the present study may have been too stringent, and samples 
that may have had informative CNV data have been excluded. 
 
In sum, we have conducted an initial CNV analysis in the NIA-LOAD/NCRAD Family 
Study dataset. A trend towards a lower CNV call rate for deletions as well as 
duplications was observed in AD participants compared to controls. A number of gene 
regions were identified from the gene-based association analyses including those 
reported in the ADNI study (CHRFAM7A, NRXN1 and ERBB4) as well as a new gene 
(IMMP2L). The candidate gene analysis of this dataset and the ADNI study 
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simultaneously identified a statistically significant set of five genes (ATXN1, HLA-DPB1, 
RELN, DOPEY2 and GSTT1). Additional replication in other independent data sets will 
be important to confirm these findings. Future studies to elucidate the biological role of 
these variants appear warranted. Overall, some consistency of CNVs across AD cohorts 
is emerging and this variation holds promise for revealing novel risk factors and disease 
mechanisms.  
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IV. Analysis of Copy Number Variation in Alzheimer’s Disease in a Cohort of 
Clinically Characterized and Neuropathologically Verified Individuals 
 
A. Introduction 
 
Alzheimer’s disease (AD) is the most common form of dementia characterized by loss of 
memory and other cognitive abilities, severe enough to disrupt daily life activities. An 
estimated 5.4 million Americans have AD, the sixth leading cause of death across all 
ages in the United States [1]. No treatments at present can slow or halt its progression. 
Amnestic mild cognitive impairment (MCI) is a clinical condition in which a person has 
memory problems not normal for his/her age, but not severe enough to interfere 
significantly with daily functioning. Approximately 14-18% of individuals aged 70 years 
and older have MCI, and every year 10-15% of these individuals will likely progress to 
dementia, particularly AD [2]. 
 
Genetic factors play a key role in AD development accounting for approximately 58-79% 
of the phenotypic variation [4]. Mutations in APP, PSEN1 and PSEN2 primarily cause 
early-onset AD (age at onset<60 or 65 years) [5]. The leading genetic risk factor for the 
more common late-onset AD (age at onset>60 or 65 years) is the APOE ε4 allele. Large 
case-control genome-wide association studies (GWASs) have identified and replicated 
other AD risk loci including: CLU, CR1, PICALM, BIN1, EXOC3L2, MTHFD1L, 
MS4A4A/MS4A6E, CD2AP, CD33, ABCA7 and CUGBP2 [12-19]. However it is 
estimated that the APOE ε4 allele accounts for approximately 20% and the non-APOE 
loci cumulatively account for as much as 35% of the AD risk [17, 194]. Thus the loci do 
not explain all the genetic variation associated with AD, and other forms of genetic 
variation such as copy number variations (CNVs) may play a role. 
98 
CNVs are DNA regions (one kilobase (kb) to several megabases (Mb) in size) that have 
differences in copy number. These can result in the addition (copy number gains or 
duplications) or loss (copy number losses or deletions) of genetic material. CNVs often 
encompass a single gene or multiple genes and may affect their function [34]. The role 
of CNVs in late-onset AD has been investigated in prior studies [26, 129-131]. 
Previously, we analyzed the role of CNVs in AD and MCI using data from participants in 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study (described in Chapter II 
and [159]) and the National Institute of Aging-Late Onset AD/National Cell Repository for 
AD (NIA-LOAD/NCRAD) Family Study (described in Chapter III and [195]). For both 
studies, DNA extracted either from peripheral blood or brain tissue were used. 
Case/control association analyses including candidate gene and genome-wide 
approaches were performed to determine genes overlapped by CNVs only in cases (AD 
and/or MCI) but not controls. A number of genes were identified in the two studies 
including ATXN1, CHRFAM7A, CSMD1, DOPEY2, ERBB4, GSTT1, HLA-DPB1, 
HNRNPCL1, IMMP2L, NRXN1, RELN and SLC35F2. 
 
In the present report, we analyzed the role of CNVs in AD using data from a unique 
cohort of clinically characterized and neuropathologically defined cases (AD) and 
controls (TGen cohort) [196]. All DNA samples were extracted from brain tissue. 
Case/control association analyses similar to the two previous studies were performed to 
determine the CNV burden in cases relative to controls and genes overlapped by CNVs 
detected in cases but not controls. 
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B. Methods 
 
1. Samples 
 
The TGen cohort included samples extracted from brain tissue of 1617 Caucasian 
individuals (1022 AD cases and 595 controls). Recruitment information for the 
participants has been previously described [196]. Briefly, the United States cohort was 
obtained from 21 National Institute on Aging-supported Alzheimer's Disease Center 
brain banks and from the Miami Brain Bank [197, 198]. Cohorts from other brain banks 
in the United States, United Kingdom, and the Netherlands were obtained similar to the 
original United States cohort. De-identification of samples was done before receipt, and 
the study met human studies institutional review board and the Health Insurance 
Portability and Accountability Act of 1996 regulations. The present work is declared not 
human-subjects research and is institutional review board exempt under regulation 45 
CFR 46. Genome-wide genotyping for all samples was performed using the Affymetrix 
Genome-Wide Human SNP 6.0 Array (Santa Clara, CA, USA) as previously described 
[196]. APOE genotyping was done using Crook et al.'s (1994) method [199] or using a 
fluorescence-based allele-specific polymerase chain reaction (PCR), also called PCR 
Amplification of Specific Alleles, on array tape [200] by PreventionGenetics (Marshfield, 
WI, USA). 
 
The ADNI data used in the preparation of the present report were obtained from the 
Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.ucla.edu) 
as described in Chapter II and [159]. ADNI's primary goal is to test whether imaging 
markers, genetic markers, other biological markers, and clinical and neuropsychological 
assessments can be combined to measure progression of MCI and early AD. More 
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information on ADNI can be found on http://www.adni-info.org/. The Illumina Human610-
Quad BeadChip (San Diego, CA, USA) was used to perform genome-wide genotyping of 
the ADNI sample as previously described [137, 159]. The APOE polymorphisms 
(rs429358 and rs7412) were genotyped separately. 
 
The NIA-LOAD/NCRAD Family Study data used in the present report were obtained 
from the "NIA-Late Onset Alzheimer's Disease and National Cell Repository for 
Alzheimer's Disease Family Study: Genome-Wide Association Study for Susceptibility 
Loci" dataset (dbGaP Study Accession: phs000168.v1.p1, Project #2026) on the 
database of Genotypes and Phenotypes (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000168.v1.p1) website as described in Chapter III and [195]. 
Recruitment information for NIA-LOAD Family Study and NCRAD participants has been 
previously described [19]. Genome-wide genotyping for all samples was performed 
using the Illumina Human610-Quad BeadChip at the Center for Inherited Disease 
Research (Baltimore, MD, USA). The APOE polymorphisms (rs429358 and rs7412) 
were genotyped at PreventionGenetics. 
 
2. Generation of copy number variation calls and quality control 
 
CNV calls were generated for the 1617 TGen samples using PennCNV (2011Jun16 
version; http://www.openbioinformatics.org/penncnv/) [68], a Hidden Markov model 
based program. The PennCNV-Affy protocol 
(http://www.openbioinformatics.org/penncnv/penncnv_tutorial_affy_gw6.html) for the 
Affymetrix Genome-Wide Human SNP 6.0 Array was first performed to transform raw 
CEL files into a signal intensity file containing the Log R Ratio (LRR) and B Allele 
Frequency (BAF) values used by PennCNV to generate CNV calls. The Hidden Markov 
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model “affygw6.hmm”, population frequency of B allele “affygw6.hg18.pfb” and gcmodel 
“affygw6.hg18.gcmodel” files were used. Extensive quality control (QC) was performed 
on all samples. A genomic wave adjustment procedure using PennCNV’s gcmodel file 
was applied as samples that have below optimal genomic wave QC values can be 
considered unreliable [138]. Frequency distribution plots of the number of CNV calls, 
LRR standard deviation (SD), BAF Drift and Waviness Factor (WF) were made. A 
sample was excluded if at least one of the above measures for the sample was greater 
than 90th percentile of the frequency distribution, i.e. the sample had >56 CNV calls, LRR 
SD>0.38, BAF Drift>0.01 or WF>0.02. 
 
Due to complications of hemizygosity in males and X-chromosome inactivation in 
females, analyses were restricted to autosomes. To ensure we were including only high-
confidence CNVs in the analysis, CNVs for which the difference of the log likelihood of 
the most likely copy number state and less likely copy number state was <10, CNVs 
called based on data <10 SNPs, and CNVs that had >50% overlap with centromeric, 
telomeric, and immunoglobulin regions as defined in Need et al. (2009) [140] were 
excluded. CNV calls were not filtered for size because both large and small variants 
could be of potential significance. A case sample observed to have a very large (~8.4 
Mb) deletion on chromosome 19, and a control sample observed to have a very large 
(~22.4 Mb) duplication on chromosome 1, were excluded from the analyses as they may 
be possible outliers. The ~8.4 Mb deletion on chromosome 19 encompassed both sides 
of the centromere, but did not overlap any RefSeq or UCSC Genes according to the 
UCSC Genome Browser (http://genome.ucsc.edu/) [142]. 1166 samples (728 cases, 438 
controls) with 31045 CNV calls remained after all QC measures and were entered into 
case/control association analyses. 
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3. Case/control association analyses 
 
Case/control association analyses in the TGen study were performed similar to the ADNI 
[159] and NIA-LOAD/NCRAD Family [195] studies. PLINK v1.07 
(http://pngu.mgh.harvard.edu/~purcell/plink/) [141] was used to investigate CNV call 
differences between cases (AD) and controls. Two approaches were used: a candidate 
gene approach including 317 AD genes identified from the AlzGene database (Updated 
5 January 2011) (http://www.alzgene.org/) [8] as having a positive association with AD in 
at least one study, and a genome-wide approach using 17938 genes from PLINK’s gene 
list (hg18 coordinates). The AlzGene database is a publicly available online resource 
that provides a comprehensive and regularly updated catalog of genetic case/control 
and family association studies in AD. In both approaches, CNV segments either partially 
or completely overlapping genes were analyzed. The analyses included both deletions 
and duplications. 
 
4. Meta-analysis 
 
We performed a meta-analysis for the CHRFAM7A gene using results from the ADNI, 
NIA-LOAD/NCRAD Family and TGen studies to determine differences in frequency of 
CNV calls overlapping the gene between cases (AD or MCI) and controls. A fixed-effects 
model was run and a summary odds ratio (OR) was calculated using the Mantel 
Haenszel method. MetaAnalyst Beta 3.13 (http://tuftscaes.org/meta_analyst/index.html) 
[201] and Comprehensive Meta-Analysis Version 2 [202] were used for the meta-
analysis and generation of the forest plot (Figure 15). The UCSC Genome Browser 
(http://genome.ucsc.edu/) [142] (March 2006 (NCBI36/hg18) assembly) was used to 
create representative plots of the CNV calls (Figures 13 and 14). The Genome Browser 
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track for the Affymetrix Genomewide 6.0 array was obtained from the PennCNV website 
(http://www.openbioinformatics.org/penncnv/penncnv_download.html).  
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C. Results 
 
1. Sample demographics and copy number variation call characteristics 
 
The sample demographics and CNV call characteristics of the 728 cases and 438 
controls who passed all QC measures are shown in Tables 13 and 14. Significant 
(p<0.05; two-sided) differences in gender, absence or presence of the APOE ε4 allele, 
age at death, Braak stage and the Consortium to Establish a Registry for Alzheimer's 
Disease (CERAD) score were observed between cases and controls. 31045 CNV calls 
(24188 deletions and 6857 duplications) were observed with an average of 45 SNPs per 
CNV call and an average CNV call length of 64.76 kb. A higher CNV call rate and a 
lower average CNV call size were observed in deletions compared to duplications. Rates 
of deletions and duplications did not significantly differ between cases and controls. 
There were no significant differences in the rates of deletions and rates of duplications 
when males and females were analyzed separately (data not shown). A large proportion 
of deletions and duplications were found in the 0.1-0.5 Mb size range (Table 15). 
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Table 13. Sample demographics in the TGen cohort. CERAD-The Consortium to 
Establish a Registry for Alzheimer’s Disease. 
 
 Cases Controls p (two-sided) 
Number of samples 728 438 - 
Gender (Males/Females) 180/548 274/164 <0.001 
APOE group (ε4 negative/ 
ε4 positive) 
93/173 138/45 <0.001 
Age at onset 72.84±6.14 (n=60) - - 
Age at death 82.46±7.58 (n=266) 80.80±9.17 (n=183) 0.037 
Braak stage 5.09±0.83 (n=168) 1.62±0.76 (n=96) <0.001 
CERAD score 2.31±0.84 (n=26) 0.83±0.64 (n=47) <0.001 
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Table 14. Characteristics of copy number variation calls from samples in the TGen 
cohort. CNV-Copy number variation. 
 
 Cases (n=728) Controls (n=438) 
Deletions: 
Number of CNVs 
Rate per sample 
Average size (kb) 
 
15177 
20.85 
45.34 
 
9011 
20.57 
46.75 
Duplications: 
Number of CNVs 
Rate per sample 
Average size (kb) 
 
4334 
5.95 
140.8 
 
2523 
5.76 
131.1 
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Table 15. TGen samples grouped by copy number variation call size. 
 
Call size Cases (n=728) Controls (n=438) 
 Deletions 
n (%) 
Duplications 
n (%) 
Deletions 
n (%) 
Duplications 
n (%) 
0.1-0.5 Mb 647 (88.87) 625 (85.85) 387 (88.36) 368 (84.02) 
0.5-1.0 Mb 95 (13.05) 164 (22.53) 61 (13.93) 101 (23.06) 
1.0-1.5 Mb 10 (1.37) 25 (3.43) 7 (1.60) 12 (2.74) 
1.5-2.0 Mb 4 (0.55) 7 (0.96) 0 (0.00) 2 (0.46) 
>2.0 Mb 2 (0.27) 11 (1.51) 5 (1.14) 1 (0.23) 
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2. Case/control association analyses 
 
2.1. Candidate gene approach 
 
We identified 32 candidate genes in the TGen study overlapped by CNV calls from at 
least one case (AD) but no controls (Table 16). Representative plots of two genes (APP 
and DOPEY2) are shown in Figure 13. The HLA-DRA gene was overlapped by deletions 
in nine cases (uncorrected p=0.0140; one-sided). This gene was also found to be 
overlapped by deletions in two controls in the ADNI study. Two genes (RELN overlapped 
by deletions in two cases and DOPEY2 overlapped by duplications in four cases) 
identified in this study were also reported from only cases (AD and/or MCI) in the ADNI 
and NIA-LOAD/NCRAD Family studies. One AD sample (APOE ε2/ε3 genotype, age at 
death=67) had a novel APP gene duplication supported by 443 sequential SNP and 
CNV probes. The CHRFAM7A gene reported in the ADNI and NIA-LOAD/NCRAD 
Family studies was overlapped by deletions in 10 cases and two controls, and 
duplications in 12 cases and one control (corrected p=0.0198; one-sided) in this study 
(Figure 14). 
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Table 16. Genes overlapped by copy number variation calls from at least one case 
and no control samples in the TGen cohort using the candidate gene approach. aA 
case sample had copy number variation calls overlapping the AGT, LHCGR and BAT1 
genes; b,c,dThree different case samples had copy number variation calls overlapping the 
HLA-DRA and HLA-E, HLA-DRA and HLA-DQB1, and HLA-DRA and NGB genes 
respectively; eA different case sample had copy number variation calls overlapping the 
MYH13 and MYH8 genes. 
 
Chromosome Region Start (bp) End (bp) Number of cases 
1 FAM63A 149234172 149245957 1 
1 SOAT1 177529639 177591076 1 
1 AGT 228904891 228916959 1a 
2 LHCGR 48767416 48836384 4a 
6 HLA-G 29902734 29906878 1 
6 HLA-A 30018309 30021633 2 
6 HLA-E 30565249 30569072 3b 
6 BAT1 31605974 31618204 1a 
6 HLA-DRA 32515624 32520802 9b,c,d 
6 HLA-DQB1 32735634 32742444 1c 
7 MAGI2 77484309 78920826 1 
7 CD36 80069439 80146529 1 
7 RELN 102899472 103417198 2 
8 NAT2 18293034 18303003 1 
10 ALDH18A1 97355675 97406557 1 
10 EBF3 131523536 131652081 1 
11 PICALM 85346132 85457756 1 
12 C12orf41 47333261 47362302 3 
12 ALDH2 110688728 110732167 2 
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Chromosome Region Start (bp) End (bp) Number of cases 
14 PSEN1 72672931 72756862 1 
14 NGB 76801586 76807408 1d 
17 SERPINF2 1592879 1605309 1 
17 MYH13 10144907 10217047 2e 
17 MYH8 10234366 10265992 1e 
17 MAPT 41327543 41461546 1 
19 GALP 61379200 61388956 1 
21 APP 26174731 26465003 1 
21 DOPEY2 36458708 36588442 4 
21 CBS 43346369 43369493 1 
21 S100B 46842958 46849463 1 
22 COMT 18309308 18336530 1 
22 BCR 21852551 21990224 1 
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Figure 13. Representative UCSC Genome Browser (March 2006 (NCBI36/hg18) 
assembly) plots of duplications overlapping the candidate genes APP (A) and 
DOPEY2 (B) in samples of the TGen cohort. The chromosomal location of the gene 
and probes on the Affymetrix SNP 6.0 Structural Variation array are shown. The region 
with the duplication for each sample relative to the gene is represented by a blue 
rectangle. 
 
  
      A 
 
 
      B 
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Figure 14. Representative UCSC Genome Browser (March 2006 (NCBI36/hg18) 
assembly) plots of deletions and duplications overlapping the CHRFAM7A gene in 
samples of the TGen cohort. The chromosomal location of the gene and probes on the 
Affymetrix SNP 6.0 Structural Variation array are shown. The region with the deletion for 
each sample relative to the gene is highlighted by a red rectangle and the region with the 
duplication for each sample relative to the gene is highlighted by a blue rectangle. 
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2.2. Genome-wide approach 
 
We also identified genes across the genome overlapped by CNV calls only in cases 
(AD) but not controls in the TGen study. The HLA-DRA gene identified in the candidate 
gene approach was also found from this approach (uncorrected p=0.0144; one-sided). 
The CHRFAM7A gene was also identified from this approach (uncorrected p=0.0046; 
one-sided). Genes reported in the ADNI and NIA-LOAD/NCRAD Family studies were 
overlapped by CNV calls in this study including: CSMD1 (deletions in 65 cases and 32 
controls, duplications in one case and one control), ERBB4 (deletions in 71 cases and 
35 controls, duplication in one control), HNRNPCL1 (deletions in 19 cases and eight 
controls, duplications in one case and two controls), IMMP2L (deletions in six cases and 
five controls, duplication in one control), NRXN1 (deletions in two cases and three 
controls), and SLC35F2 (duplications in two cases and one control). 
 
3. Meta-analysis 
 
A meta-analysis for the CHRFAM7A gene was performed using findings from the ADNI, 
NIA-LOAD/NCRAD Family and TGen studies (Table 17 and Figure 15). Overall, the 
gene was overlapped by CNV calls in 38 of 1797 (2.115%) cases (AD or MCI) and four 
of 752 (0.532%) controls. A significant association was observed for the gene with AD or 
MCI risk (summary OR=3.986; 95% confidence interval (CI), 1.490-10.667; p=0.006). On 
repeating the analysis with only the AD cases and not the MCI cases in the ADNI cohort, 
a significant association for the gene with AD risk (summary OR=3.952; 95% CI, 1.471-
10.617) was observed. 
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Table 17. Meta-analysis of the CHRFAM7A gene. CNV-Copy number variation. 
 
Cohort ADNI 
(n=501) 
NIA-LOAD/NCRAD 
(n=882) 
TGen 
(n=1166) 
Overall 
(n=2549) 
Cases: 
Number of samples 
CNV overlapping 
gene (n) 
No CNV overlapping 
gene (n) 
 
358 
4 
 
354 
 
711 
12 
 
699 
 
728 
22 
 
706 
 
1797 
38 
 
1759 
Controls: 
Number of samples 
CNV overlapping 
gene (n) 
No CNV overlapping 
gene (n) 
 
143 
0 
 
143 
 
171 
1 
 
170 
 
438 
3 
 
435 
 
752 
4 
 
748 
Odds ratio 3.643 2.918 4.518 3.986 
95% confidence 
interval 
0.195-68.103 0.377-22.599 1.344-15.185 1.490-10.667 
p 0.387 0.305 0.015 0.006 
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Figure 15. Forest plot of the CHRFAM7A gene. The plot represents the meta-analysis 
of the CHRFAM7A gene using results from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) study, the National Institute of Aging-Late Onset AD/National Cell 
Repository for AD (NIA-LOAD/NCRAD) Family Study and the TGen study. The odds 
ratio and 95% confidence interval for the odds ratio for each study are represented by 
black squares and horizontal lines. The summary odds ratio is depicted as a black 
diamond. OR-Odds ratio; CI-Confidence interval. 
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D. Discussion 
 
The present report represents an initial CNV analysis in the TGen cohort, a unique 
cohort of clinically characterized and neuropathologically verified individuals. After 
extensive QC, case (AD)/control association analyses using candidate gene and 
genome-wide approaches were performed. Genes enriched in cases relative to controls 
were determined, suggesting possible involvement of these genes in AD susceptibility. 
 
Rates of deletions and duplications did not significantly differ between cases and 
controls. This is different from findings in the ADNI and NIA-LOAD/NCRAD Family 
studies and could be due to different participant selection criteria, random sampling 
variation, different QC criteria, and that the NIA-LOAD/NCRAD Family Study and TGen 
study analyses included only AD and control samples, whereas the ADNI study analyses 
included MCI samples in addition to AD and control samples. 
 
The candidate gene approach revealed a number of interesting genes (Table 16 and 
Figure 13). The HLA-DRA (major histocompatibility complex, class II, DR alpha) gene on 
chromosome 6 is a human leukocyte antigen (HLA) class II alpha chain paralogue which 
plays an important role in the immune system by presenting peptides derived from 
extracellular proteins. Variants in HLA-DRA have been associated with Parkinson 
disease [203, 204] and multiple sclerosis [205, 206], but not with AD. Other HLA alleles 
however have been investigated for a possible role in AD [174, 175, 207, 208]. 
 
The CHRFAM7A (CHRNA7 (cholinergic receptor, nicotinic, alpha 7, exons 5-10) and 
FAM7A (family with sequence similarity 7A, exons A-E) fusion) gene (Figure 14) is 
located on chromosome 15. It is formed as a hybrid of a partially duplicated CHRNA7 
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gene and the FAM7A gene [145, 167]. It is highly polymorphic and individuals with and 
without this gene have been identified. A 2-bp deletion polymorphism at position 497-
498 in exon 6 of this gene has been observed to be significantly over-represented in 
participants with AD, dementia with Lewy bodies and Pick’s disease compared to 
controls [147]. 
 
Although CHRFAM7A is transcribed, its translation and possible function of the resulting 
protein is uncertain. The gene is expressed in the hippocampus, a brain region known to 
be first affected in AD. Recently, it has been suggested to possibly modulate α7 subunit 
receptor-mediated synaptic transmission and cholinergic anti-inflammatory response 
[168]. It may also be a dominant negative modulator of CHRNA7 function and important 
for receptor regulation in humans [169]. A meta-analysis using gene results from the 
ADNI, NIA-LOAD/NCRAD Family and TGen studies revealed a significant association of 
the gene with AD or MCI risk (Table 17 and Figure 15). On repeating the analysis with 
only the AD cases and not the MCI cases in the ADNI cohort, a significant association 
for the gene with AD risk was observed. 
 
Two genes (RELN and DOPEY2) in the three studies were found to be overlapped by 
CNV calls from cases (AD and/or MCI) but not controls. The RELN (reelin) gene on 
chromosome 7 encodes the glycoprotein reelin, which activates a signaling pathway 
required for proper positioning of neurons within laminated nervous system parenchyma. 
Gene variants have been associated with AD [176] and the protein has been observed 
to have increased expression in pyramidal neurons of the hippocampus in AD individuals 
and in cognitively intact controls with AD-associated pathology [177]. The DOPEY2 
(dopey family member 2, also known as C21orf5) gene located on chromosome 21 in 
the Down syndrome critical region is a potential Down syndrome candidate gene [178, 
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209]. Overexpression of the gene may be associated with the neurological phenotypes 
and mental retardation observed in Down syndrome patients. One AD sample was 
identified with an APP gene duplication, representing a novel finding since APP 
duplications have been associated with early-onset [81, 125, 210] but not late-onset AD. 
The genes identified from the candidate gene approach have been previously 
investigated in AD studies and thus represent potential candidate genes. Replication in 
independent samples and laboratory validation can help confirm the role of these genes 
in AD susceptibility. 
 
The genome-wide approach revealed the candidate genes: HLA-DRA and CHRFAM7A 
as well as identified genes reported in the two previous studies. The CSMD1, 
HNRNPCL1, IMMP2L and SLC35F2 genes have not been previously associated with 
AD. The NRXN1 gene has been associated with autism [85], schizophrenia [91], and 
has been shown to have reduced expression with increasing AD severity [150]. The 
ERBB4 gene may play a possible role in the progression of AD pathology [187-189]. 
 
It is important to note the limitations of the present report. Although the same software 
(PennCNV) was used in the three studies, different QC criteria were used for the 
selection of samples. The ADNI and NIA-LOAD/NCRAD Family study samples were 
genotyped on the Illumina Human610-Quad BeadChip and used similar QC criteria. The 
TGen study samples were genotyped on the Affymetrix Genome-Wide Human SNP 6.0 
Array and thus we used a slightly different QC criteria. To our knowledge, there does not 
appear to be consensus on a well defined set of QC criteria for inclusion of the most 
appropriate samples in CNV analyses. The QC criterion applied in the present study 
may have been too stringent, leading to samples possibly having informative CNV data 
being excluded. A direct comparison of CNV calls from the three studies would be 
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difficult as two different genotyping platforms were used. Probes from the two platforms 
may not correspond with each other with respect to their location. Replication in 
additional independent data sets and future molecular studies will help confirm the 
findings. 
 
In sum, we have conducted an initial CNV analysis in samples from a cohort of clinically 
characterized and neuropathologically verified individuals. Rates of deletions and 
duplications did not significantly differ between cases and controls. Gene-based 
association analysis identified a number of genes including those reported in the ADNI 
and NIA-LOAD/NCRAD Family studies (CHRFAM7A, RELN and DOPEY2) as well as a 
new gene (HLA-DRA). Meta-analysis from the three studies revealed a significant 
association for CHRFAM7A with AD and/or MCI risk. Replication in independent 
samples will be necessary to confirm these findings. Targeted analyses of the identified 
regions will help determine the biological role of these variants. Overall, there appears to 
be some consistency of CNVs across AD cohorts and this variation holds promise for 
revealing novel risk factors and disease mechanisms. 
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V. Summary and Future Directions 
 
Genetic variation is an important risk factor in the development of Alzheimer's disease 
(AD). The disease has been shown to have a high heritability with 58-79% of phenotypic 
variation estimated to be caused by genetic factors [4]. Mutations in the APP, PSEN1 
and PSEN2 genes cause early-onset AD (onset earlier than 60 or 65 years), but these 
account for approximately one to six percent of all AD cases. The leading genetic risk 
factor for the more common late-onset AD (onset later than 60 or 65 years) is the APOE 
ε4 allele. Recent genome-wide association studies (GWASs) have identified and 
replicated other AD risk loci including: CLU, CR1, PICALM, BIN1, EXOC3L2, MTHFD1L, 
MS4A4A/MS4A6E, CD2AP, CD33, ABCA7 and CUGBP2 [12-19]. However, not all 
genetic variation associated with AD is explained by these loci, and other forms of 
genetic variation such as copy number variations (CNVs) may play a role. 
 
CNVs are DNA regions ranging from one kilobase (kb) to several megabases (Mb) in 
size that have added genetic material (copy number gains or duplications) or loss of 
genetic material (copy number losses or deletions). They play a role in various 
neuropsychiatric disorders such as autism [85, 86, 102], Parkinson disease [89, 90, 113] 
and schizophrenia [91, 92, 114]. At the time of starting this work, only one published 
study had examined the role of CNVs in late-onset AD [26]. The authors of the study 
identified a duplication in the CHRNA7 gene which they thought warranted further 
investigation. The role of CNVs in mild cognitive impairment (MCI) had not been 
investigated at the time. 
 
We thus performed a genome-wide CNV analyses in 288 AD, 183 MCI, and 184 control 
participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) study [134] who 
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had DNA samples extracted from peripheral blood. Participants whose DNA samples 
were extracted from cell lines were excluded from the analyses as CNV results could be 
influenced by cell line transformation [135, 136]. Case/control association analyses were 
performed to compare the CNV burden between cases (AD and/or MCI) and controls, 
and to identify genomic regions where CNVs could be detected in cases but not controls. 
A trend towards a higher CNV call rate for deletions and a lower CNV rate for 
duplications was observed in cases compared to controls. Case/control association 
analyses identified a number of genes including: CHRFAM7A, an AD candidate gene; 
NRXN1 and ERBB4, genes associated with neuropsychiatric disorders [85, 143]; and 
CSMD1, HNRNPCL1 and SLC35F2, genes not previously associated with AD. 
 
We then performed a similar genome-wide CNV analyses in 794 AD and 196 
neurologically evaluated control non-Hispanic Caucasian participants in the National 
Institute of Aging-Late Onset AD/National Cell Repository for AD (NIA-LOAD/NCRAD) 
Family Study [19] who had DNA samples extracted from peripheral blood or brain tissue. 
The controls were unrelated to AD participants and had no family history of AD. 
Case/control association analyses were performed using similar methods and quality 
control (QC) criteria as in the ADNI study. We observed a trend for lower CNV call rate 
for deletions as well as duplications in cases compared to controls. Case/control 
association analyses identified genes reported in the ADNI study (ATXN1, CHRFAM7A, 
DOPEY2, ERBB4, GSTT1, HLA-DPB1, NRXN1 and RELN) as well as a new gene 
(IMMP2L). This gene is disrupted in patients with Tourette syndrome [182, 183], but has 
not been previously associated with AD. 
 
We then performed a similar genome-wide CNV analyses in a third cohort of 1022 AD 
and 595 control Caucasian participants who had DNA samples extracted from brain 
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tissue. This is a unique cohort of clinically characterized and neuropathologically verified 
cases (AD) and controls [196]. As samples in this study were genotyped using the 
Affymetrix Genome-Wide Human SNP 6.0 Array, and samples in the ADNI and NIA-
LOAD/NCRAD Family studies were genotyped using the Illumina Human610-Quad 
BeadChip, we applied a different set of QC criteria for samples in this study. However, 
we used similar methods for the case/control association analyses. Rates of deletions 
and duplications did not significantly differ between cases and controls. A number of 
genes were identified from the case/control association analyses including those 
reported in the ADNI and NIA-LOAD/NCRAD Family studies (CHRFAM7A, RELN and 
DOPEY2) as well as a new gene (HLA-DRA). The HLA-DRA gene has been associated 
with Parkinson disease [203, 204] and multiple sclerosis [205, 206], but has not been 
associated with AD. A meta-analysis of the CHRFAM7A findings from the three studies 
revealed a significant association for the CHRFAM7A gene with AD or MCI risk 
(summary OR=3.986; 95% CI, 1.490-10.667). On repeating the analysis with only the 
AD cases and not the MCI cases in the ADNI cohort, a significant association for the 
gene with AD risk (summary OR=3.952; 95% CI, 1.471-10.617) was observed. 
 
Thus, the present work includes genome-wide CNV analyses in three independent 
cohorts of AD, MCI and control participants. A number of possible candidate genes were 
identified warranting further investigation. Future directions of this work include 
replication in independent datasets and molecular validation to confirm the findings. 
Other cohorts of AD, control and possibly MCI participants who have DNA samples 
extracted from peripheral blood and/or brain tissue and genotype data can be used for 
replication analyses. Gene-based association analyses using similar approaches as the 
present work can be performed. Genes reported in the present work can be analyzed in 
these cohorts to determine if a higher proportion of cases have CNVs overlapping the 
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gene compared to controls thus replicating the findings in the present work. Also, if the 
identified CNVs overlapping the gene have similar length and location in multiple 
individuals, these may help identify specific regions within the gene that may be 
disrupted by the CNVs possibly affecting gene function. These regions would be 
potential targets for further investigation. 
 
After possible candidate regions have been identified using bioinformatics approaches, 
the regions need to be validated using molecular techniques to confirm the copy number 
of these regions. Few techniques used for molecular validation of CNV results are: 
quantitative real-time polymerase chain reaction (qPCR), multiplex ligation-dependent 
probe amplification and multiple amplifiable probe hybridization, comparative genome 
hybridization (CGH) arrays or array CGH, and targeted resequencing. 
 
qPCR with TaqMan copy number assays is a commonly used technique to validate 
CNVs. The assays are run simultaneously in the qPCR along with a TaqMan copy 
number reference assay. The target gene or genomic sequence of interest is amplified 
by the copy number assay. A sequence known to exist in a diploid genome in two copies 
such as the RNase P H1 RNA gene is amplified by the reference assay. The target 
sequence copy number in each test sample is determined by relative quantitation using 
the comparative Ct method. Cycle threshold (Ct) determines the qPCR cycles needed to 
obtain sufficient product to detect fluorescent signal in this assay. The Ct difference 
between target and reference sequences is measured, after which a comparison of the 
Ct difference values of test samples to a calibrator sample known to have two copies of 
the target sequence is performed [211]. The target copy number is calculated as two 
times the relative quantity. 
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Two other techniques which can be used for validation are multiplex ligation-dependent 
probe amplification and multiple amplifiable probe hybridization. These are targeted 
PCR-based approaches that can be used to analyze multiple genomic regions up to 40 
target sequences simultaneously. In these approaches, oligonucleotide probes are used 
to generate locus-specific amplicons that can be resolved by capillary electrophoresis. 
Duplications are indicated by enhanced peak signals and deletions are indicated by 
reduced peak signals [47, 52]. 
 
Array CGH is another technique that can be used to perform validation experiments. In 
this technique, two fluorescently labeled samples (test and reference) are competitively 
hybridized to a known target DNA sequence immobilized on a solid glass substrate. The 
signal ratio between the test and reference sample after normalization and conversion to 
a log2 ratio acts as a proxy for copy number. A gain in copy number in the test sample 
compared with the reference sample is indicated by an increased log2 ratio; conversely, 
a loss in copy number is indicated by a decrease in log2 ratio [212]. Custom arrays are 
available from manufacturers such as Roche NimbleGen and Agilent Technologies that 
can be used for targeted analyses. 
 
Targeted resequencing of candidate regions can also be used to perform validation 
experiments. In this technique, DNA is extracted from the sample and purified. The DNA 
is then enriched using one of the following methods: PCR, long-range PCR, array 
hybridization, in-solution hybridization, or chromosome sorting. DNA libraries (fragment 
libraries and mate-paired libraries) are constructed and the DNA is amplified using 
standard emulsion PCR. Sequencing is performed on specialized systems such as the 
Applied Systems SOLiD System and the data generated is analyzed. Results can then 
be validated using systems such as the Applied Systems VariantSEQr Resequencing 
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System (http://www.appliedbiosystems.com/absite/us/en/home/applications-
technologies/solid-next-generation-sequencing/targeted-resequencing.html). 
Sequencing can be performed on the whole gene or just the protein coding portion of the 
gene (the exome). Systems such as the Applied Biosystems TargetSeq Exome 
Enrichment System, which is based on an in-solution hybridization method for exome 
capture, can be used for performing exome sequencing. Methods to detect CNVs from 
whole genome or exome sequencing data are being developed [213, 214]. We will be 
receiving whole genome sequencing data for DNA samples in the ADNI cohort which will 
enable us to interrogate the regions identified in the CNV analyses. We also have 
proteomic data for samples in this cohort collected using the Human DiscoveryMAP 
panel from Myriad RBM and are planning RNA expression studies, thus enabling us to 
determine possible downstream effects of the CNVs on transcription and translation of 
the overlapped regions. 
 
After the CNVs have been molecularly validated, their clinical significance will need to be 
determined. One approach would be to determine if the CNV is inherited or de novo in 
nature. If the CNV is inherited from a healthy parent or similar to a CNV in a healthy 
relative, it is likely that the CNV is benign [215, 216]. If the CNV is inherited from an 
affected parent or similar to a CNV in an affected relative, it is likely that the CNV is 
pathogenic. Databases such as the Toronto Database of Genomic Variants 
(http://projects.tcag.ca/variation/) [36], DECIPHER (Database of Chromosomal 
Imbalance and Phenotype in Humans Using Ensembl Resources; 
http://decipher.sanger.ac.uk/) [37] and ECARUCA (European Cytogeneticists 
Association Register of Unbalanced Chromosome Alterations; 
http://umcecaruca01.extern.umcn.nl:8080/ecaruca/ecaruca.jsp) [38] can be used to 
determine the clinical relevance of de novo CNVs. Targeted analysis of the overlapped 
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regions in a large number of case and control samples can help determine the utility of 
these regions for genetic testing and counseling. 
 
In sum, AD represents an important disease in society for which there is an urgent need 
to find a cure. The number of people surviving into the oldest ages (80’s and 90’s) is 
expected to dramatically increase because of medical advances as well as better social 
and economic conditions [1]. With the growing number of older people, it is anticipated 
that there would be an increase in the number of existing and new cases of AD and 
dementia. Ongoing research work focused on determining the causes of AD may lead to 
its earlier diagnosis and better treatment. Genetic variation plays a key role in AD 
development and progression, but recent GWASs have not identified all the genetic 
factors associated with the disease. Other forms of genetic variation such as CNVs 
which play a role in neuropsychiatric disorders [34] have not been extensively studied in 
AD and MCI. CNV analyses conducted in the present work have revealed a number of 
possible candidate regions warranting further investigation. The findings in the present 
work suggest the possible involvement of other forms of structural genetic variation in 
disease susceptibility. Further studies including targeted resequencing and other 
approaches may help determine this.          
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